[
  {
    "patient_id": "1",
    "patient_data": {
      "ID": 1,
      "beschreibung": "G1-Case",
      "tumorboard_datum ": 12.2024,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G1 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 Resektion der Lebermetastasen in Segment VI und Ablation der Läsion in Segment VIII. Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.\n01/2017 V.a. neue Lebermetastase\n02/2017 Start Somatoline\n02/2018 CT Abdomen: stable disease\n03/2019 CT Abdomen: V.a. gering progrediente Lebermetastasen. ",
      "Fragestellung": "Weitere Therapie?",
      "Empfehlung": "PET- Bildgebung und PRRT planen."
    },
    "matches_found": 15,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03278379",
        "title": "Avelumab in G2-3 NET",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": ".1:\nClinical Relevance Assessment: NCT03278379 for the Patient\nBased on the provided patient and study data, NCT03278379 is likely clinically relevant for this patient, but with some uncertainties due to missing patient information. Here's a breakdown of why, addressing each of the four conditions for clinical relevance:\n1. Tumor Type and Characteristics Match:\n Yes. The study specifically includes patients with neuroendocrine tumors (NET) of gastroenteropancreatic or lung origin. The patient has a NET of the small intestine (Dünndarm), which falls under the gastroenteropancreatic category.\n2. Inclusion/Exclusion Criteria Do Not Rule Out the Patient (Based on Available Information):\n Age: The patient's age is not specified, but the study includes patients ≥ 18 years. This is not a known exclusion.\n Performance Status: The patient's ECOG is not specified, but the study accepts ECOG 0-2. We cannot definitively say if the patient meets this criterion without knowing their ECOG score.\n Prior Therapies: The patient received somatostatin analogs. The study allows prior treatment with up to 2 lines of systemic therapy excluding somatostatin analogs as a line of therapy. The patient's treatment history is not fully detailed, but the somatostatin analog use is allowed as long as it has been ceased.\n Tumor Grade: The patient's tumor is G1. The study excludes G1 NETs and only includes G2-3. This is a significant exclusion criterion.\n Disease Stage: The patient has metastatic disease to the liver and lymph nodes. The study requires unresectable or metastatic disease, which the patient has.\n Organ Function: The study requires adequate liver and renal function. The patient's liver function is not explicitly stated, but the CT scans show progression despite somatostatin analogs, suggesting the liver metastases are still present. Renal function is also unknown.\n Other Criteria: The study has other criteria regarding blood counts, etc. which we cannot assess without more patient data.\n3. Intervention is Potentially Useful:\n Yes. Avelumab is an anti-PD-L1 antibody, an immunotherapy agent. Immunotherapy is a potential treatment option for advanced NETs, and this study is investigating its efficacy in this setting.\n4. Published Results of Good Scientific Quality:\n Yes. The study is completed and has published results, indicating a level of scientific rigor.\nOverall Conclusion: While the study could be relevant, the G1 tumor grade is a major exclusion criterion. The patient's tumor is G1, while the study only includes G2-3 tumors. \nFurther Information Needed:\n Confirmation of Tumor Grade: A definitive confirmation of the tumor grade (G1 vs. G2/G3) is crucial. If the initial pathology was incorrect and the tumor is actually G2 or G3, the study would be highly relevant.\n ECOG Performance Status: Knowing the patient's ECOG score is essential to determine if they meet the inclusion criteria.\n Liver and Renal Function: Laboratory values for liver and renal function are needed to assess eligibility.\n Detailed Treatment History: A complete list of prior therapies and dates is needed to confirm eligibility regarding the somatostatin analog use.\nDisclaimer: I am an AI assistant and cannot provide medical advice. This assessment is based solely on the information provided and should be reviewed by a qualified healthcare professional.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Avelumab",
        "url": "https://clinicaltrials.gov/study/NCT03278379",
        "publications": {
          "nct_id": "NCT03278379",
          "study_title": "Avelumab in G2-3 NET",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35504244",
              "citation": "Chan DL, Rodriguez-Freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A, Nguyen K, Singh S. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. Eur J Cancer. 2022 Jul;169:74-81. doi: 10.1016/j.ejca.2022.03.029. Epub 2022 May 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35504244/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02730104",
        "title": "Community-based Neuroendocrine Tumor (NET) Research Study",
        "status": "COMPLETED",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a well-differentiated (G1) small bowel NET with liver metastases, which falls within the study's inclusion criteria of gastroenteropancreatic NETs (small bowel specifically). The patient is currently on somatostatin analogue therapy (Somatoline), and the study allows for prior treatment with octreotide (and implicitly, lanreotide). While the patient's age, ECOG status, and biomarker data are unknown, the provided exclusion criteria do not immediately disqualify them. The study is completed, has published results, and investigates lanreotide, which is a potentially useful treatment option given the patient's disease progression.",
        "condition": "Gastroenteropancreatic Neuroendocrine Tumors",
        "intervention": "",
        "url": "https://clinicaltrials.gov/study/NCT02730104",
        "publications": {
          "nct_id": "NCT02730104",
          "study_title": "Community-based Neuroendocrine Tumor (NET) Research Study",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "36136274",
              "citation": "Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. Oncol Ther. 2022 Dec;10(2):463-479. doi: 10.1007/s40487-022-00208-1. Epub 2022 Sep 22.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/36136274/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02973204",
        "title": "Circulating Tumor Cells and Tumor DNA in HCC and NET",
        "status": "COMPLETED",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors (NET), matching the patient's diagnosis. The patient's history of somatostatin analogue treatment (Somatoline) aligns with one of the treatment arms investigated in the study (Somatostatin Analogue). While the patient has progressed on Somatoline, the study's focus on biomarkers to predict treatment response and monitor disease course could still be valuable for guiding further therapy decisions. The study is completed and has 16 publications, indicating good scientific quality and available results.",
        "condition": "Carcinoma, Hepatocellular; Neuroendocrine Tumors",
        "intervention": "Sorafenib; Radiofrequency ablation (RFA) or surgery; Everolimus; Lanreotide",
        "url": "https://clinicaltrials.gov/study/NCT02973204",
        "publications": {
          "nct_id": "NCT02973204",
          "study_title": "Circulating Tumor Cells and Tumor DNA in HCC and NET",
          "publications_found": 16,
          "publications": [
            {
              "pmid": "25140861",
              "citation": "Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jantti C, Sundin A, Sundlov A, Thiis-Evensen E, Knigge U. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25140861/"
            },
            {
              "pmid": "21374666",
              "citation": "Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21374666/"
            },
            {
              "pmid": "22846862",
              "citation": "Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol. 2012 Aug;39(4):449-60. doi: 10.1053/j.seminoncol.2012.05.012.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22846862/"
            },
            {
              "pmid": "21224371",
              "citation": "Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M, Meyer T. Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res. 2011 Jan 15;17(2):337-45. doi: 10.1158/1078-0432.CCR-10-1776. Epub 2011 Jan 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21224371/"
            },
            {
              "pmid": "23248251",
              "citation": "Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013 Jan 20;31(3):365-72. doi: 10.1200/JCO.2012.44.2905. Epub 2012 Dec 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23248251/"
            },
            {
              "pmid": "23616258",
              "citation": "Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013 Nov;133(9):2165-71. doi: 10.1002/ijc.28230. Epub 2013 Jun 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23616258/"
            },
            {
              "pmid": "25009297",
              "citation": "Guo W, Yang XR, Sun YF, Shen MN, Ma XL, Wu J, Zhang CY, Zhou Y, Xu Y, Hu B, Zhang X, Zhou J, Fan J. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res. 2014 Sep 15;20(18):4794-805. doi: 10.1158/1078-0432.CCR-14-0251. Epub 2014 Jul 9.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25009297/"
            },
            {
              "pmid": "24185511",
              "citation": "Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec;45(12):1483-6. doi: 10.1038/ng.2821. Epub 2013 Nov 3.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24185511/"
            },
            {
              "pmid": "21252315",
              "citation": "Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011 Mar 4;331(6021):1199-203. doi: 10.1126/science.1200609. Epub 2011 Jan 20.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21252315/"
            },
            {
              "pmid": "24148618",
              "citation": "Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24148618/"
            },
            {
              "pmid": "25900181",
              "citation": "Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris TJ, Salomoni P, Luong TV, Davidson B, Beck S, Thirlwell C. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015 Jun;22(3):L13-8. doi: 10.1530/ERC-15-0108. Epub 2015 Apr 21. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25900181/"
            },
            {
              "pmid": "19496710",
              "citation": "Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009 Jun;9(6):739-45. doi: 10.1586/era.09.41.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19496710/"
            },
            {
              "pmid": "25822088",
              "citation": "Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25822088/"
            },
            {
              "pmid": "24705333",
              "citation": "Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW Jr, Alizadeh AA, Diehn M. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. Epub 2014 Apr 6.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24705333/"
            },
            {
              "pmid": "25103305",
              "citation": "Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014 Dec 15;120(24):3896-901. doi: 10.1002/cncr.28964. Epub 2014 Aug 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25103305/"
            },
            {
              "pmid": "25991462",
              "citation": "Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open. 2015 May 19;5(5):e008248. doi: 10.1136/bmjopen-2015-008248.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25991462/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03012620",
        "title": "Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for this patient. The study explicitly includes 'rare malignant neuroendocrine tumour' patients, specifically those refractory to prior lines of treatment, which aligns with the patient's history of progressing disease after initial treatment and subsequent somatostatin analogue therapy. The inclusion criteria regarding metastatic disease and prior treatment lines appear to be met, although ECOG performance status and age are unknown. Pembrolizumab, an anti-PD-1 antibody, represents a potentially useful treatment option for progressing NET, and the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "condition": "Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal; NK/T-cell Lymphoma",
        "intervention": "Pembrolizumab",
        "url": "https://clinicaltrials.gov/study/NCT03012620",
        "publications": null
      },
      {
        "nct_id": "NCT03012789",
        "title": "Surgical Intervention and the NETest",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for this patient. The patient has a well-differentiated (G1) NET of gastro-enteropancreatic origin, matching the study's inclusion criteria regarding tumor type. The patient's history of prior treatments (somatostatin analogue and resection) doesn't exclude them, as the study includes patients who have received previous therapies and are currently on LAR with stable disease. While ECOG and age are not specified, the patient appears eligible based on the WHO performance status of ≤2. The study's focus on surgical resection and correlation with NETest results could inform further treatment decisions, and the presence of three publications indicates good scientific quality.",
        "condition": "Neuroendocrine Tumor; Gastroenteropancreatic",
        "intervention": "Surgery",
        "url": "https://clinicaltrials.gov/study/NCT03012789",
        "publications": {
          "nct_id": "NCT03012789",
          "study_title": "Surgical Intervention and the NETest",
          "publications_found": 3,
          "publications": [
            {
              "pmid": "26456125",
              "citation": "Modlin IM, Frilling A, Salem RR, Alaimo D, Drymousis P, Wasan HS, Callahan S, Faiz O, Weng L, Teixeira N, Bodei L, Drozdov I, Kidd M. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 2016 Jan;159(1):336-47. doi: 10.1016/j.surg.2015.06.056. Epub 2015 Oct 9.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26456125/"
            },
            {
              "pmid": "26032155",
              "citation": "Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol. 2015 Aug;110(8):1223-32. doi: 10.1038/ajg.2015.160. Epub 2015 Jun 2.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26032155/"
            },
            {
              "pmid": "26370353",
              "citation": "Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015 Sep;16(9):e435-e446. doi: 10.1016/S1470-2045(15)00186-2.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26370353/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03333616",
        "title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The inclusion criteria explicitly mention 'genitourinary carcinoma with neuroendocrine differentiation', which encompasses the patient's diagnosis of a neuroendocrine tumor (NET) of the small intestine. While the study focuses on genitourinary tumors, the inclusion of neuroendocrine carcinomas makes it potentially applicable. The patient's history of prior surgery and somatostatin treatment doesn't appear to be exclusionary based on the provided criteria, and the combination of nivolumab and ipilimumab could be a useful treatment option given disease progression. The study has published results, indicating a level of scientific rigor.",
        "condition": "Genitourinary Cancer; Adrenocortical Carcinoma; Non-urothelial Bladder; Non-urothelial Upper Tract; Penile Cancer; Non-adenocarcinoma Prostate Cancer; Refractory Germ-cell; High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma",
        "intervention": "Ipilimumab; Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT03333616",
        "publications": {
          "nct_id": "NCT03333616",
          "study_title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33216356",
              "citation": "McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021 Mar 15;127(6):840-849. doi: 10.1002/cncr.33328. Epub 2020 Nov 20.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33216356/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02724540",
        "title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, matching the patient's diagnosis. The inclusion criteria regarding liver metastases (≥ 1.0 cm) and tumor burden seem to align with the patient’s case, as they have liver metastases. The patient is currently on somatostatin analogues, which is allowed per the inclusion criteria, and is seeking further therapy for potentially progressive disease, fitting the study's aim. The study is Phase 2, completed, has published results, and the interventions (embolization techniques) represent a potentially useful treatment option for liver metastases in NET patients.",
        "condition": "Neuroendocrine Tumor, Malignant; Liver Metastases",
        "intervention": "Bland Embolization; Transarterial chemoembolization; Drug Eluting Beads Embolization",
        "url": "https://clinicaltrials.gov/study/NCT02724540",
        "publications": {
          "nct_id": "NCT02724540",
          "study_title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30016989",
              "citation": "Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018 Jul 17;19(1):390. doi: 10.1186/s13063-018-2782-5.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30016989/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT05168631",
        "title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, matching the patient's diagnosis of a small intestinal NET. The patient's metastatic disease (liver metastases) fits the inclusion criterion of 'metastatic or inoperable disease'. While the patient's age and prior therapies are not specified, the study doesn't have restrictive criteria regarding these factors. The study's aim to identify prognostic and predictive factors could inform further treatment decisions for the patient, and the presence of 15 publications indicates good scientific quality and reported results.",
        "condition": "Neuroendocrine Tumors; Carcinoma;Endocrine",
        "intervention": "",
        "url": "https://clinicaltrials.gov/study/NCT05168631",
        "publications": {
          "nct_id": "NCT05168631",
          "study_title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
          "publications_found": 15,
          "publications": [
            {
              "pmid": "18565894",
              "citation": "Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/18565894/"
            },
            {
              "pmid": "25312765",
              "citation": "Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015 Feb 15;121(4):589-97. doi: 10.1002/cncr.29099. Epub 2014 Oct 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25312765/"
            },
            {
              "pmid": "28448665",
              "citation": "Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28448665/"
            },
            {
              "pmid": "27759713",
              "citation": "Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27759713/"
            },
            {
              "pmid": "25723112",
              "citation": "Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25723112/"
            },
            {
              "pmid": "28955403",
              "citation": "de M Rego JF, de Medeiros RSS, Braghiroli MI, Galvao B, Neto JEB, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, de Castro G Jr, Hoff PM, Filho DR, Costa FP, Riechelmann RP. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience. 2017 Sep 11;11:767. doi: 10.3332/ecancer.2017.767. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28955403/"
            },
            {
              "pmid": "26482044",
              "citation": "Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016 Feb 15;22(4):1011-7. doi: 10.1158/1078-0432.CCR-15-0548. Epub 2015 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26482044/"
            },
            {
              "pmid": "28018101",
              "citation": "Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28018101/"
            },
            {
              "pmid": "28456055",
              "citation": "Girardi DM, Silva ACB, Rego JFM, Coudry RA, Riechelmann RP. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev. 2017 May;56:28-35. doi: 10.1016/j.ctrv.2017.04.002. Epub 2017 Apr 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28456055/"
            },
            {
              "pmid": "27259015",
              "citation": "Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016 Sep;40(9):1192-202. doi: 10.1097/PAS.0000000000000662.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27259015/"
            },
            {
              "pmid": "29629316",
              "citation": "Oberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg. 2018 Feb;7(1):20-27. doi: 10.21037/gs.2017.10.08.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29629316/"
            },
            {
              "pmid": "27594907",
              "citation": "Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016 Aug 8;10:662. doi: 10.3332/ecancer.2016.662. eCollection 2016.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27594907/"
            },
            {
              "pmid": "28194228",
              "citation": "Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenco Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience. 2017 Jan 26;11:716. doi: 10.3332/ecancer.2017.716. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28194228/"
            },
            {
              "pmid": "19097774",
              "citation": "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19097774/"
            },
            {
              "pmid": "7165009",
              "citation": "Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7165009/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT06638931",
        "title": "Agnostic Therapy in Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for this patient. The patient has a neuroendocrine tumor of the small intestine with liver metastases, which is explicitly listed in the study's inclusion criteria as 'Pure or mixed neuroendocrine tumors with neuroendocrine component'. While the patient's ECOG and age are unknown, the study requires an ECOG of 0 or 1 and age over 18, which are plausible for this patient. The patient has progressed on prior treatment (Somatoline), meeting the requirement for progression after standard therapies. Nivolumab, an immunotherapy, is a potentially useful treatment option given the progression of the disease. The study has published results in peer-reviewed journals, indicating good scientific quality.",
        "condition": "Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor",
        "intervention": "Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT06638931",
        "publications": {
          "nct_id": "NCT06638931",
          "study_title": "Agnostic Therapy in Rare Solid Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "25542058",
              "citation": "Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporte I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25542058/"
            },
            {
              "pmid": "35320644",
              "citation": "Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35320644/"
            },
            {
              "pmid": "30204247",
              "citation": "DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30204247/"
            },
            {
              "pmid": "26028255",
              "citation": "Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26028255/"
            },
            {
              "pmid": "34534430",
              "citation": "Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34534430/"
            },
            {
              "pmid": "32919526",
              "citation": "Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32919526/"
            },
            {
              "pmid": "30955977",
              "citation": "Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30955977/"
            },
            {
              "pmid": "32101663",
              "citation": "Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32101663/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02923934",
        "title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, specifically intestinal carcinoid tumors which aligns with the patient's diagnosis of a small intestinal NET. The inclusion criteria do not appear to rule the patient out based on the limited information available; the patient would need to meet ECOG performance status of 1 and have measurable disease, but these are plausible. The combination of ipilimumab and nivolumab is a potentially useful treatment option given the patient's progressing disease after initial treatment and the lack of specified prior systemic therapies. Finally, the study is completed and has published results, indicating good scientific quality.",
        "condition": "Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm",
        "intervention": "Ipilimumab; Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT02923934",
        "publications": {
          "nct_id": "NCT02923934",
          "study_title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "32729929",
              "citation": "Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32729929/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03870399",
        "title": "Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a well-differentiated NET of the small intestine, which falls within the inclusion criteria of the study (NET G1/G2 of gastroenteropancreatic sites). While the patient's ECOG and age are unknown, the study accepts ECOG 0-2. The patient has progressing liver metastases and has already received somatostatin analogs, suggesting a need for further therapy, aligning with the study's inclusion of patients with progressing disease and limited treatment options. The study has published results in 21 publications, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors; Progesterone Receptor Positive Tumor; Estrogen Receptor Positive Tumor",
        "intervention": "Tamoxifen",
        "url": "https://clinicaltrials.gov/study/NCT03870399",
        "publications": {
          "nct_id": "NCT03870399",
          "study_title": "Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression",
          "publications_found": 21,
          "publications": [
            {
              "pmid": "18565894",
              "citation": "Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/18565894/"
            },
            {
              "pmid": "9737302",
              "citation": "Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998 Sep 5;352(9130):799-805. doi: 10.1016/S0140-6736(98)02286-7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/9737302/"
            },
            {
              "pmid": "19845567",
              "citation": "Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88. doi: 10.1111/j.1365-2036.2009.04174.x. Epub 2009 Oct 21.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19845567/"
            },
            {
              "pmid": "25317881",
              "citation": "Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Oct 16;371(16):1556-7. doi: 10.1056/NEJMc1409757. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25317881/"
            },
            {
              "pmid": "19704057",
              "citation": "Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19704057/"
            },
            {
              "pmid": "1356613",
              "citation": "Viale G, Doglioni C, Gambacorta M, Zamboni G, Coggi G, Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992 Nov 1;70(9):2268-77. doi: 10.1002/1097-0142(19921101)70:93.0.co;2-x.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/1356613/"
            },
            {
              "pmid": "26976979",
              "citation": "Zimmermann N, Lazar-Karsten P, Keck T, Billmann F, Schmid S, Brabant G, Thorns C. Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases. Anticancer Res. 2016 Mar;36(3):921-4.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26976979/"
            },
            {
              "pmid": "25076292",
              "citation": "Estrella JS, Broaddus RR, Mathews A, Milton DR, Yao JC, Wang H, Rashid A. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug;138(8):1027-36. doi: 10.5858/arpa.2013-0195-OA.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25076292/"
            },
            {
              "pmid": "28597868",
              "citation": "Kim SJ, An S, Lee JH, Kim JY, Song KB, Hwang DW, Kim SC, Yu E, Hong SM. Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients. J Pathol Transl Med. 2017 Jul;51(4):388-395. doi: 10.4132/jptm.2017.03.19. Epub 2017 Jun 8.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28597868/"
            },
            {
              "pmid": "2800857",
              "citation": "Arganini M, Spinelli C, Cecchini GM, Miccoli P. Long term treatment with tamoxifen for metastatic carcinoid tumor. Acta Chir Belg. 1989 Jul-Aug;89(4):209-11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/2800857/"
            },
            {
              "pmid": "7059114",
              "citation": "Myers CF, Ershler WB, Tannenbaum MA, Barth R. Tamoxifen and carcinoid tumor. Ann Intern Med. 1982 Mar;96(3):383. doi: 10.7326/0003-4819-96-3-383_1. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7059114/"
            },
            {
              "pmid": "25702678",
              "citation": "Biasco E, Antonuzzo A, Galli L, Baldi GG, Derosa L, Marconcini R, Farnesi A, Ricci S, Falcone A. Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen. Tumori. 2015 Mar 20;101(1):e24-8. doi: 10.5301/tj.5000259.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25702678/"
            },
            {
              "pmid": "7231519",
              "citation": "Stathopoulos GP, Karvountzis GG, Yiotis J. Tamoxifen in carcinoid syndrome. N Engl J Med. 1981 Jul 2;305(1):52. doi: 10.1056/NEJM198107023050115. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7231519/"
            },
            {
              "pmid": "6200021",
              "citation": "Moertel CG, Engstrom PF, Schutt AJ. Tamoxifen therapy for metastatic carcinoid tumor: a negative study. Ann Intern Med. 1984 Apr;100(4):531-2. doi: 10.7326/0003-4819-100-4-531. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/6200021/"
            },
            {
              "pmid": "10334533",
              "citation": "Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 May;17(5):1474-81. doi: 10.1200/JCO.1999.17.5.1474.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/10334533/"
            },
            {
              "pmid": "16148022",
              "citation": "Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005 Oct;16(10):1569-83. doi: 10.1093/annonc/mdi326. Epub 2005 Sep 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/16148022/"
            },
            {
              "pmid": "22173704",
              "citation": "Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012 Feb;7(2):306-15. doi: 10.1097/JTO.0b013e31823c5c16.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22173704/"
            },
            {
              "pmid": "28018101",
              "citation": "Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28018101/"
            },
            {
              "pmid": "6438654",
              "citation": "Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25(2):127-205. doi: 10.1016/0163-7258(84)90043-3. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/6438654/"
            },
            {
              "pmid": "9875847",
              "citation": "Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23;95(7):927-37. doi: 10.1016/s0092-8674(00)81717-1.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/9875847/"
            },
            {
              "pmid": "21306238",
              "citation": "Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21306238/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03074513",
        "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes a 'Neuroendocrine tumors, extrapancreatic basket' which aligns with the patient's diagnosis of a small intestinal NET. The patient's history of stable disease on somatostatin analogs and progression suggests they have exhausted initial treatment options, making them a candidate for a new systemic therapy. The inclusion/exclusion criteria do not appear to rule the patient out based on the limited information available (specifically, the patient's age and ECOG status are not specified but would need to meet the study requirements). The study has published results, indicating good scientific quality.",
        "condition": "Appendix Adenocarcinoma; Human Papillomavirus-Related Anal Squamous Cell Carcinoma; Human Papillomavirus-Related Cervical Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis; Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma; Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor; Recurrent Merkel Cell Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Stage III Merkel Cell Carcinoma AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Carcinoma AJCC v7; Stage IV Pleural Malignant Mesothelioma AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVC Nasopharyngeal Carcinoma AJCC v7; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "intervention": "Atezolizumab; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study",
        "url": "https://clinicaltrials.gov/study/NCT03074513",
        "publications": {
          "nct_id": "NCT03074513",
          "study_title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35389428",
              "citation": "Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jun 1;8(6):904-909. doi: 10.1001/jamaoncol.2022.0212.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35389428/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT05050942",
        "title": "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a well-differentiated NET of the small intestine with liver metastases, which falls under the GEP-NET category included in the study. The inclusion criteria (age ≥18, ECOG 0-2, measurable lesions) don't explicitly exclude the patient, although the patient's ECOG and age are not specified. The study investigates octreotide LAR, a treatment the patient has already received (Somatoline is an octreotide formulation), and explores a potentially more effective alternative (CAM2029) for progressive disease, directly addressing the clinical question of further therapy. The study has published results, indicating good scientific quality.",
        "condition": "Gastro-enteropancreatic Neuroendocrine Tumor",
        "intervention": "CAM2029; Octreotide LAR; Lanreotide ATG",
        "url": "https://clinicaltrials.gov/study/NCT05050942",
        "publications": null
      },
      {
        "nct_id": "NCT03873870",
        "title": "68Ga-DOTATATE PET for Management of Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with NETs, matching the patient's diagnosis. The patient's history of progressing disease despite somatostatin analogs and potential consideration of PRRT aligns with inclusion criteria Group C (Restaging). While the patient's age, ECOG, and prior therapies are unknown, there are no explicit exclusion criteria mentioned that would immediately rule them out. The study has published results and focuses on improving diagnostic accuracy which could impact treatment decisions, making it potentially useful in determining further therapy options for this patient.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "68Ga -DOTATATE PET scans",
        "url": "https://clinicaltrials.gov/study/NCT03873870",
        "publications": null
      },
      {
        "nct_id": "NCT02754297",
        "title": "Personalized PRRT of Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with progressive NET (the patient has potentially progressing liver metastases), and the patient's history of surgical resection and somatostatin analogue treatment suggests they may be ineligible or have progressed beyond other options, fitting the inclusion criteria. The use of 177Lu-Octreotate PRRT is a reasonable next step for a patient with somatostatin receptor-positive NET, and the study's personalization approach could be beneficial. The study has published results, indicating good scientific quality. While the patient's ECOG status and age are unknown, they are not explicitly ruled out by the exclusion criteria.",
        "condition": "Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine",
        "intervention": "177Lu-Octreotate",
        "url": "https://clinicaltrials.gov/study/NCT02754297",
        "publications": {
          "nct_id": "NCT02754297",
          "study_title": "Personalized PRRT of Neuroendocrine Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30506283",
              "citation": "Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742. doi: 10.1007/s00259-018-4209-7. Epub 2018 Nov 30.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30506283/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ]
  },
  {
    "patient_id": "2",
    "patient_data": {
      "ID": 2,
      "beschreibung": "G3-Case Initialdiagnose, Netter 2 analo",
      "tumorboard_datum ": 8.2015,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.",
      "Fragestellung": "Weitere Therapie?",
      "Empfehlung": "PET- Bildgebung und PRRT planen, analog zur Netter 2 Studie."
    },
    "matches_found": 15,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03278379",
        "title": "Avelumab in G2-3 NET",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with advanced neuroendocrine tumors of gastroenteropancreatic origin, which matches the patient's diagnosis of a small intestinal NET with liver metastases. The inclusion criteria allow for patients who have received up to two prior lines of systemic therapy, and the patient's prior hemicolektomy and resection don't automatically exclude them. While the patient's ECOG and age are unknown, the study accepts ECOG 0-2. Avelumab, an anti-PD-L1 antibody, represents a potentially useful treatment option given the patient's progression and the lack of specified further therapy. The study is completed and has published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Avelumab",
        "url": "https://clinicaltrials.gov/study/NCT03278379",
        "publications": {
          "nct_id": "NCT03278379",
          "study_title": "Avelumab in G2-3 NET",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35504244",
              "citation": "Chan DL, Rodriguez-Freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A, Nguyen K, Singh S. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. Eur J Cancer. 2022 Jul;169:74-81. doi: 10.1016/j.ejca.2022.03.029. Epub 2022 May 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35504244/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02973204",
        "title": "Circulating Tumor Cells and Tumor DNA in HCC and NET",
        "status": "COMPLETED",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors (NET), matching the patient's diagnosis. The inclusion criteria are broad and do not immediately exclude the patient based on the limited information available (age and ECOG are not specified, and there's no mention of other cancers). The study investigates biomarkers to guide treatment decisions, which directly addresses the clinical question of 'further therapy?'. Finally, the study has 16 publications and posted results, indicating good scientific quality and meaningful findings.",
        "condition": "Carcinoma, Hepatocellular; Neuroendocrine Tumors",
        "intervention": "Sorafenib; Radiofrequency ablation (RFA) or surgery; Everolimus; Lanreotide",
        "url": "https://clinicaltrials.gov/study/NCT02973204",
        "publications": {
          "nct_id": "NCT02973204",
          "study_title": "Circulating Tumor Cells and Tumor DNA in HCC and NET",
          "publications_found": 16,
          "publications": [
            {
              "pmid": "25140861",
              "citation": "Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jantti C, Sundin A, Sundlov A, Thiis-Evensen E, Knigge U. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25140861/"
            },
            {
              "pmid": "21374666",
              "citation": "Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21374666/"
            },
            {
              "pmid": "22846862",
              "citation": "Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol. 2012 Aug;39(4):449-60. doi: 10.1053/j.seminoncol.2012.05.012.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22846862/"
            },
            {
              "pmid": "21224371",
              "citation": "Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M, Meyer T. Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res. 2011 Jan 15;17(2):337-45. doi: 10.1158/1078-0432.CCR-10-1776. Epub 2011 Jan 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21224371/"
            },
            {
              "pmid": "23248251",
              "citation": "Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013 Jan 20;31(3):365-72. doi: 10.1200/JCO.2012.44.2905. Epub 2012 Dec 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23248251/"
            },
            {
              "pmid": "23616258",
              "citation": "Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013 Nov;133(9):2165-71. doi: 10.1002/ijc.28230. Epub 2013 Jun 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23616258/"
            },
            {
              "pmid": "25009297",
              "citation": "Guo W, Yang XR, Sun YF, Shen MN, Ma XL, Wu J, Zhang CY, Zhou Y, Xu Y, Hu B, Zhang X, Zhou J, Fan J. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res. 2014 Sep 15;20(18):4794-805. doi: 10.1158/1078-0432.CCR-14-0251. Epub 2014 Jul 9.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25009297/"
            },
            {
              "pmid": "24185511",
              "citation": "Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec;45(12):1483-6. doi: 10.1038/ng.2821. Epub 2013 Nov 3.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24185511/"
            },
            {
              "pmid": "21252315",
              "citation": "Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011 Mar 4;331(6021):1199-203. doi: 10.1126/science.1200609. Epub 2011 Jan 20.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21252315/"
            },
            {
              "pmid": "24148618",
              "citation": "Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24148618/"
            },
            {
              "pmid": "25900181",
              "citation": "Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris TJ, Salomoni P, Luong TV, Davidson B, Beck S, Thirlwell C. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015 Jun;22(3):L13-8. doi: 10.1530/ERC-15-0108. Epub 2015 Apr 21. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25900181/"
            },
            {
              "pmid": "19496710",
              "citation": "Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009 Jun;9(6):739-45. doi: 10.1586/era.09.41.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19496710/"
            },
            {
              "pmid": "25822088",
              "citation": "Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25822088/"
            },
            {
              "pmid": "24705333",
              "citation": "Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW Jr, Alizadeh AA, Diehn M. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. Epub 2014 Apr 6.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24705333/"
            },
            {
              "pmid": "25103305",
              "citation": "Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014 Dec 15;120(24):3896-901. doi: 10.1002/cncr.28964. Epub 2014 Aug 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25103305/"
            },
            {
              "pmid": "25991462",
              "citation": "Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open. 2015 May 19;5(5):e008248. doi: 10.1136/bmjopen-2015-008248.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25991462/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03012620",
        "title": "Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for this patient. The study explicitly includes 'rare malignant neuroendocrine tumour' patients, specifically those refractory to prior lines of treatment, which aligns with the patient's advanced disease and history of surgery. While the patient's prior therapies are not specified, the study accepts patients refractory to 2 or more lines of chemotherapy or 4 lines of treatment for well-differentiated tumors, and the patient's G3, high Ki67 tumor suggests a more aggressive disease course. The intervention, pembrolizumab, is a potentially useful treatment option given the patient's progression. The study is a completed Phase 2 trial with published results, indicating good scientific quality.",
        "condition": "Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal; NK/T-cell Lymphoma",
        "intervention": "Pembrolizumab",
        "url": "https://clinicaltrials.gov/study/NCT03012620",
        "publications": null
      },
      {
        "nct_id": "NCT03012789",
        "title": "Surgical Intervention and the NETest",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes G3 NETs of gastro-enteropancreatic origin, which matches the patient’s small bowel NET. The inclusion criteria allow for both treatment-naive and previously treated patients, and the WHO performance status of ≤2 is likely met given the limited information available. The study's focus on surgical resection and correlation with NETest results could be useful in determining if further surgical intervention or monitoring is warranted, addressing the clinical question of 'further therapy?'. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumor; Gastroenteropancreatic",
        "intervention": "Surgery",
        "url": "https://clinicaltrials.gov/study/NCT03012789",
        "publications": {
          "nct_id": "NCT03012789",
          "study_title": "Surgical Intervention and the NETest",
          "publications_found": 3,
          "publications": [
            {
              "pmid": "26456125",
              "citation": "Modlin IM, Frilling A, Salem RR, Alaimo D, Drymousis P, Wasan HS, Callahan S, Faiz O, Weng L, Teixeira N, Bodei L, Drozdov I, Kidd M. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 2016 Jan;159(1):336-47. doi: 10.1016/j.surg.2015.06.056. Epub 2015 Oct 9.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26456125/"
            },
            {
              "pmid": "26032155",
              "citation": "Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol. 2015 Aug;110(8):1223-32. doi: 10.1038/ajg.2015.160. Epub 2015 Jun 2.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26032155/"
            },
            {
              "pmid": "26370353",
              "citation": "Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015 Sep;16(9):e435-e446. doi: 10.1016/S1470-2045(15)00186-2.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26370353/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03333616",
        "title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The inclusion criteria explicitly mention 'genitourinary carcinoma with neuroendocrine differentiation', which encompasses the patient's diagnosis of a neuroendocrine tumor. While the primary focus is on genitourinary tumors, the inclusion of neuroendocrine carcinomas makes it a potential option. The patient's prior surgery doesn't automatically exclude them, and the study's intervention (nivolumab and ipilimumab) represents a potentially useful immunotherapy approach for metastatic NET. The study has published results, indicating a level of scientific rigor and quality.",
        "condition": "Genitourinary Cancer; Adrenocortical Carcinoma; Non-urothelial Bladder; Non-urothelial Upper Tract; Penile Cancer; Non-adenocarcinoma Prostate Cancer; Refractory Germ-cell; High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma",
        "intervention": "Ipilimumab; Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT03333616",
        "publications": {
          "nct_id": "NCT03333616",
          "study_title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33216356",
              "citation": "McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021 Mar 15;127(6):840-849. doi: 10.1002/cncr.33328. Epub 2020 Nov 20.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33216356/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02724540",
        "title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, and the patient has a confirmed diagnosis of a G3 small bowel NET with liver metastases. The inclusion criteria regarding liver metastasis size and tumor burden seem potentially met, and the patient's prior surgery doesn't exclude them. The interventions (bland embolization, TACE, DEB) are reasonable treatment options for progressive liver metastases in NET patients when other therapies have failed or are not suitable. The study is completed, has published results, and is a phase 2 trial, indicating a good level of scientific rigor.",
        "condition": "Neuroendocrine Tumor, Malignant; Liver Metastases",
        "intervention": "Bland Embolization; Transarterial chemoembolization; Drug Eluting Beads Embolization",
        "url": "https://clinicaltrials.gov/study/NCT02724540",
        "publications": {
          "nct_id": "NCT02724540",
          "study_title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30016989",
              "citation": "Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018 Jul 17;19(1):390. doi: 10.1186/s13063-018-2782-5.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30016989/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03079440",
        "title": "TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a Grade 3 NET of the small intestine, which falls within the study's inclusion criteria of gastrointestinal NETs with a Ki-67 > 20% (patient's Ki-67 is 48%). While the patient's ECOG and age are unknown, assuming they meet the study criteria (ECOG 0-2 and age >19), they would likely be eligible. The TEMCAP regimen offers a potentially useful alternative to standard etoposide/cisplatin chemotherapy, particularly given the study's focus on lower Ki-67 expression within Grade 3 tumors. The study has 5 publications, indicating good scientific quality and available results.",
        "condition": "Neuroendocrine Tumors; Neuroendocrine Carcinoma; Temozolomide; Capecitabine",
        "intervention": "TEMCAP",
        "url": "https://clinicaltrials.gov/study/NCT03079440",
        "publications": {
          "nct_id": "NCT03079440",
          "study_title": "TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors",
          "publications_found": 5,
          "publications": [
            {
              "pmid": "26731334",
              "citation": "Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186-94. doi: 10.1159/000443172. Epub 2016 Jan 5. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26731334/"
            },
            {
              "pmid": "24771552",
              "citation": "Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014 Sep 15;120(18):2814-23. doi: 10.1002/cncr.28721. Epub 2014 Apr 25.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24771552/"
            },
            {
              "pmid": "22967994",
              "citation": "Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22967994/"
            },
            {
              "pmid": "20824724",
              "citation": "Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011 Jan 15;117(2):268-75. doi: 10.1002/cncr.25425. Epub 2010 Sep 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/20824724/"
            },
            {
              "pmid": "21456005",
              "citation": "Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011 Oct 15;117(20):4617-22. doi: 10.1002/cncr.26124. Epub 2011 Mar 31.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21456005/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT05168631",
        "title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, matching the patient's diagnosis of a small intestinal NET. The patient's metastatic disease (liver and lymph node metastases) meets the inclusion criterion of metastatic or inoperable disease. While the patient's age, ECOG, and prior therapies are unknown, the study doesn't have restrictive criteria in those areas based on the provided information. The study's retrospective nature focusing on prognostic and predictive factors could potentially inform further treatment decisions, and the presence of 15 publications indicates good scientific quality and reported results.",
        "condition": "Neuroendocrine Tumors; Carcinoma;Endocrine",
        "intervention": "",
        "url": "https://clinicaltrials.gov/study/NCT05168631",
        "publications": {
          "nct_id": "NCT05168631",
          "study_title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
          "publications_found": 15,
          "publications": [
            {
              "pmid": "18565894",
              "citation": "Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/18565894/"
            },
            {
              "pmid": "25312765",
              "citation": "Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015 Feb 15;121(4):589-97. doi: 10.1002/cncr.29099. Epub 2014 Oct 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25312765/"
            },
            {
              "pmid": "28448665",
              "citation": "Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28448665/"
            },
            {
              "pmid": "27759713",
              "citation": "Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27759713/"
            },
            {
              "pmid": "25723112",
              "citation": "Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25723112/"
            },
            {
              "pmid": "28955403",
              "citation": "de M Rego JF, de Medeiros RSS, Braghiroli MI, Galvao B, Neto JEB, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, de Castro G Jr, Hoff PM, Filho DR, Costa FP, Riechelmann RP. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience. 2017 Sep 11;11:767. doi: 10.3332/ecancer.2017.767. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28955403/"
            },
            {
              "pmid": "26482044",
              "citation": "Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016 Feb 15;22(4):1011-7. doi: 10.1158/1078-0432.CCR-15-0548. Epub 2015 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26482044/"
            },
            {
              "pmid": "28018101",
              "citation": "Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28018101/"
            },
            {
              "pmid": "28456055",
              "citation": "Girardi DM, Silva ACB, Rego JFM, Coudry RA, Riechelmann RP. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev. 2017 May;56:28-35. doi: 10.1016/j.ctrv.2017.04.002. Epub 2017 Apr 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28456055/"
            },
            {
              "pmid": "27259015",
              "citation": "Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016 Sep;40(9):1192-202. doi: 10.1097/PAS.0000000000000662.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27259015/"
            },
            {
              "pmid": "29629316",
              "citation": "Oberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg. 2018 Feb;7(1):20-27. doi: 10.21037/gs.2017.10.08.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29629316/"
            },
            {
              "pmid": "27594907",
              "citation": "Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016 Aug 8;10:662. doi: 10.3332/ecancer.2016.662. eCollection 2016.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27594907/"
            },
            {
              "pmid": "28194228",
              "citation": "Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenco Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience. 2017 Jan 26;11:716. doi: 10.3332/ecancer.2017.716. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28194228/"
            },
            {
              "pmid": "19097774",
              "citation": "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19097774/"
            },
            {
              "pmid": "7165009",
              "citation": "Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7165009/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT06638931",
        "title": "Agnostic Therapy in Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a neuroendocrine tumor of the small intestine with liver metastases, which is explicitly listed in the study's inclusion criteria under 'Pure or mixed neuroendocrine tumors with neuroendocrine component'. While the patient's ECOG and age are unknown, the study requires ECOG 0 or 1, and age >=18, which are plausible for this patient. The patient has progressed after initial surgery and is seeking further therapy, fitting the requirement of progression after prior treatment. Nivolumab, an immunotherapy, could be a useful treatment option given the aggressive nature of the G3 NET with a high Ki67. The study has published results in peer-reviewed journals, indicating good scientific quality.",
        "condition": "Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor",
        "intervention": "Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT06638931",
        "publications": {
          "nct_id": "NCT06638931",
          "study_title": "Agnostic Therapy in Rare Solid Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "25542058",
              "citation": "Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporte I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25542058/"
            },
            {
              "pmid": "35320644",
              "citation": "Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35320644/"
            },
            {
              "pmid": "30204247",
              "citation": "DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30204247/"
            },
            {
              "pmid": "26028255",
              "citation": "Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26028255/"
            },
            {
              "pmid": "34534430",
              "citation": "Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34534430/"
            },
            {
              "pmid": "32919526",
              "citation": "Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32919526/"
            },
            {
              "pmid": "30955977",
              "citation": "Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30955977/"
            },
            {
              "pmid": "32101663",
              "citation": "Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32101663/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02923934",
        "title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes intestinal neuroendocrine tumors, matching the patient's diagnosis of a duodenal NET. While the patient's ECOG and age are not specified, the inclusion criteria of ECOG 1 and age >=18 do not immediately rule them out. The prior hemicolektomy and ileum resection are permissible given the criteria allowing prior systemic therapy completed at least 4 weeks prior to enrollment. Ipilimumab and nivolumab represent a potentially useful treatment option given the patient's question regarding further therapy and the study's investigation of immunotherapy in rare cancers. The study is completed and has published results, indicating good scientific quality.",
        "condition": "Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm",
        "intervention": "Ipilimumab; Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT02923934",
        "publications": {
          "nct_id": "NCT02923934",
          "study_title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "32729929",
              "citation": "Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32729929/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03074513",
        "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes a 'Neuroendocrine tumors, extrapancreatic basket' which aligns with the patient's diagnosis of a small intestinal NET. The patient's tumor is G3 with a Ki67 of 48%, however, the study includes Grade 1 or 2 NETs, and does not explicitly exclude G3 tumors. While the patient's ECOG and age are unknown, the study requires ECOG 0 or 1, and the patient's prior therapies are not specified, but the study allows for any number of prior therapies. Atezolizumab and bevacizumab represent a potentially useful treatment option given the metastatic nature of the disease and the lack of specified prior therapies. The study has published results, indicating good scientific quality.",
        "condition": "Appendix Adenocarcinoma; Human Papillomavirus-Related Anal Squamous Cell Carcinoma; Human Papillomavirus-Related Cervical Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis; Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma; Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor; Recurrent Merkel Cell Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Stage III Merkel Cell Carcinoma AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Carcinoma AJCC v7; Stage IV Pleural Malignant Mesothelioma AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVC Nasopharyngeal Carcinoma AJCC v7; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "intervention": "Atezolizumab; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study",
        "url": "https://clinicaltrials.gov/study/NCT03074513",
        "publications": {
          "nct_id": "NCT03074513",
          "study_title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35389428",
              "citation": "Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jun 1;8(6):904-909. doi: 10.1001/jamaoncol.2022.0212.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35389428/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03873870",
        "title": "68Ga-DOTATATE PET for Management of Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors (NETs), matching the patient's diagnosis. The patient's history of a small intestinal NET with lymph node and liver metastases falls under potential indications for 68Ga-DOTATATE PET scans, specifically Group C (restaging, considering PRRT) or Group D (problem-solving tool to impact clinical management). While the patient's ECOG and age are unknown, the exclusion criteria do not immediately rule them out. The study is completed, has published results since 2020, and therefore meets the criteria for good scientific quality.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "68Ga -DOTATATE PET scans",
        "url": "https://clinicaltrials.gov/study/NCT03873870",
        "publications": null
      },
      {
        "nct_id": "NCT02113800",
        "title": "Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a G3 NET of the small intestine with liver metastases, which falls within the inclusion criteria of the study (NET G3 or progression from lower grade). While the patient's prior therapies and ECOG status are not specified, the study allows for patients progressing after first-line platinum-based chemotherapy, and the inclusion criteria regarding ECOG (0-2) and lab values are potentially met. Everolimus is a reasonable second-line treatment option for advanced NETs, and the study has published results, indicating good scientific quality.",
        "condition": "Poorly Differentiated Malignant Neuroendocrine Carcinoma; Neuroendocrine Carcinoma, Grade 3; Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3; Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3; Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)",
        "intervention": "Everolimus (Afinitor®)",
        "url": "https://clinicaltrials.gov/study/NCT02113800",
        "publications": {
          "nct_id": "NCT02113800",
          "study_title": "Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33973550",
              "citation": "Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33973550/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02754297",
        "title": "Personalized PRRT of Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with NETs, and the patient has a well-defined diagnosis of a small bowel NET with liver metastases. The inclusion criteria focus on progressive/symptomatic NET and prior treatment failure/ineligibility, which aligns with the patient's situation as they are seeking further therapy after initial surgery. While the patient's ECOG and age are unknown, the exclusion criterion of ECOG 4 suggests the patient would be eligible if their performance status is acceptable. 177Lu-Octreotate PRRT is a standard palliative treatment option for NETs, and the personalized approach in this study could be beneficial. The study has published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine",
        "intervention": "177Lu-Octreotate",
        "url": "https://clinicaltrials.gov/study/NCT02754297",
        "publications": {
          "nct_id": "NCT02754297",
          "study_title": "Personalized PRRT of Neuroendocrine Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30506283",
              "citation": "Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742. doi: 10.1007/s00259-018-4209-7. Epub 2018 Nov 30.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30506283/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03728361",
        "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors (NET) in cohort 2, and the patient has a diagnosis of a small intestinal NET with metastases. The inclusion criteria appear to be met as the patient has advanced disease and has not received prior temozolomide or immunotherapy (based on the provided information). The combination of nivolumab and temozolomide could be a potential treatment option given the patient's progression and the lack of specified prior systemic therapies. The study has published results, indicating good scientific quality.",
        "condition": "Grade I Neuroendocrine Carcinoma; Grade II Neuroendocrine Carcinoma; Grade III Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Neuroendocrine Carcinoma; Recurrent Small Cell Lung Carcinoma; Refractory Small Cell Lung Carcinoma; Lung Cancer Stage IV; Large Cell Neuroendocrine Carcinoma; Neuroendocrine Tumors; Small Cell Lung Cancer Metastatic; Small-cell Lung Cancer",
        "intervention": "Nivolumab; Temozolomide",
        "url": "https://clinicaltrials.gov/study/NCT03728361",
        "publications": {
          "nct_id": "NCT03728361",
          "study_title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33234490",
              "citation": "Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, Ghattas C, Shah M, Konda B, Verschraegen CF, Wesolowski R, Behbehani GK, Carson WE, Otterson GA. Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. Clin Lung Cancer. 2021 Jul;22(4):e487-e497. doi: 10.1016/j.cllc.2020.10.018. Epub 2020 Nov 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33234490/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ]
  },
  {
    "patient_id": "3",
    "patient_data": {
      "ID": 3,
      "beschreibung": "G2-Case, geringe SSTR Expression",
      "tumorboard_datum ": 8.2015,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 DOTATOC PET: geringe Speicherung der Leberläsionen.\n07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.",
      "Fragestellung": "Weitere Therapie, Everolimus oder PRRT?",
      "Empfehlung": "FDG-PET und Everolimus Therapie starten."
    },
    "matches_found": 15,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03278379",
        "title": "Avelumab in G2-3 NET",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with advanced, Grade 2-3 NETs of gastroenteropancreatic origin, which matches the patient's diagnosis of a G2 NET of the small intestine with liver metastases. The inclusion criteria allow for patients who have received up to two prior lines of systemic therapy, and the patient's prior hemicolektomy and resection don't automatically exclude them. The study investigates Avelumab, an immunotherapy, which represents a potential alternative treatment option to Everolimus or PRRT being considered for the patient. Finally, the study is completed and has published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Avelumab",
        "url": "https://clinicaltrials.gov/study/NCT03278379",
        "publications": {
          "nct_id": "NCT03278379",
          "study_title": "Avelumab in G2-3 NET",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35504244",
              "citation": "Chan DL, Rodriguez-Freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A, Nguyen K, Singh S. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. Eur J Cancer. 2022 Jul;169:74-81. doi: 10.1016/j.ejca.2022.03.029. Epub 2022 May 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35504244/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02973204",
        "title": "Circulating Tumor Cells and Tumor DNA in HCC and NET",
        "status": "COMPLETED",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. It explicitly includes patients with neuroendocrine tumors (NET), specifically small intestinal NET, which matches the patient's diagnosis. The inclusion criteria are broad and do not immediately exclude the patient based on the limited information provided. The study investigates Everolimus as one of the interventions, directly addressing the clinical question of whether Everolimus is a suitable next step for the patient. Finally, the study has 16 publications and posted results, indicating good scientific quality and a completed study with available data.",
        "condition": "Carcinoma, Hepatocellular; Neuroendocrine Tumors",
        "intervention": "Sorafenib; Radiofrequency ablation (RFA) or surgery; Everolimus; Lanreotide",
        "url": "https://clinicaltrials.gov/study/NCT02973204",
        "publications": {
          "nct_id": "NCT02973204",
          "study_title": "Circulating Tumor Cells and Tumor DNA in HCC and NET",
          "publications_found": 16,
          "publications": [
            {
              "pmid": "25140861",
              "citation": "Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jantti C, Sundin A, Sundlov A, Thiis-Evensen E, Knigge U. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25140861/"
            },
            {
              "pmid": "21374666",
              "citation": "Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21374666/"
            },
            {
              "pmid": "22846862",
              "citation": "Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol. 2012 Aug;39(4):449-60. doi: 10.1053/j.seminoncol.2012.05.012.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22846862/"
            },
            {
              "pmid": "21224371",
              "citation": "Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M, Meyer T. Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res. 2011 Jan 15;17(2):337-45. doi: 10.1158/1078-0432.CCR-10-1776. Epub 2011 Jan 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21224371/"
            },
            {
              "pmid": "23248251",
              "citation": "Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013 Jan 20;31(3):365-72. doi: 10.1200/JCO.2012.44.2905. Epub 2012 Dec 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23248251/"
            },
            {
              "pmid": "23616258",
              "citation": "Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013 Nov;133(9):2165-71. doi: 10.1002/ijc.28230. Epub 2013 Jun 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23616258/"
            },
            {
              "pmid": "25009297",
              "citation": "Guo W, Yang XR, Sun YF, Shen MN, Ma XL, Wu J, Zhang CY, Zhou Y, Xu Y, Hu B, Zhang X, Zhou J, Fan J. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res. 2014 Sep 15;20(18):4794-805. doi: 10.1158/1078-0432.CCR-14-0251. Epub 2014 Jul 9.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25009297/"
            },
            {
              "pmid": "24185511",
              "citation": "Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec;45(12):1483-6. doi: 10.1038/ng.2821. Epub 2013 Nov 3.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24185511/"
            },
            {
              "pmid": "21252315",
              "citation": "Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011 Mar 4;331(6021):1199-203. doi: 10.1126/science.1200609. Epub 2011 Jan 20.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21252315/"
            },
            {
              "pmid": "24148618",
              "citation": "Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24148618/"
            },
            {
              "pmid": "25900181",
              "citation": "Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris TJ, Salomoni P, Luong TV, Davidson B, Beck S, Thirlwell C. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015 Jun;22(3):L13-8. doi: 10.1530/ERC-15-0108. Epub 2015 Apr 21. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25900181/"
            },
            {
              "pmid": "19496710",
              "citation": "Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009 Jun;9(6):739-45. doi: 10.1586/era.09.41.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19496710/"
            },
            {
              "pmid": "25822088",
              "citation": "Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25822088/"
            },
            {
              "pmid": "24705333",
              "citation": "Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW Jr, Alizadeh AA, Diehn M. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. Epub 2014 Apr 6.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24705333/"
            },
            {
              "pmid": "25103305",
              "citation": "Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014 Dec 15;120(24):3896-901. doi: 10.1002/cncr.28964. Epub 2014 Aug 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25103305/"
            },
            {
              "pmid": "25991462",
              "citation": "Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open. 2015 May 19;5(5):e008248. doi: 10.1136/bmjopen-2015-008248.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25991462/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03012620",
        "title": "Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes 'rare malignant neuroendocrine tumour' patients, specifically those refractory to prior lines of treatment, which aligns with the patient's history of a metastatic NET. While the patient's prior therapies and ECOG status are not specified, the inclusion criteria do not immediately rule them out, and the study allows for patients refractory to multiple lines of treatment. Pembrolizumab represents a potentially useful treatment option to consider alongside Everolimus or PRRT. The study is a completed Phase 2 trial with published results, indicating good scientific quality.",
        "condition": "Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal; NK/T-cell Lymphoma",
        "intervention": "Pembrolizumab",
        "url": "https://clinicaltrials.gov/study/NCT03012620",
        "publications": null
      },
      {
        "nct_id": "NCT02724540",
        "title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, and the patient has a NET of the small intestine with liver metastases. The inclusion criteria regarding liver metastasis size and tumor burden seem potentially met based on the provided information, and the patient's prior surgery doesn't exclude them. The interventions (embolization techniques) offer an alternative to the clinical question of Everolimus versus PRRT, potentially providing another treatment option for liver metastases. The study is completed, has published results, and is a phase 2 trial, indicating a reasonable level of scientific quality.",
        "condition": "Neuroendocrine Tumor, Malignant; Liver Metastases",
        "intervention": "Bland Embolization; Transarterial chemoembolization; Drug Eluting Beads Embolization",
        "url": "https://clinicaltrials.gov/study/NCT02724540",
        "publications": {
          "nct_id": "NCT02724540",
          "study_title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30016989",
              "citation": "Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018 Jul 17;19(1):390. doi: 10.1186/s13063-018-2782-5.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30016989/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT05168631",
        "title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, matching the patient's diagnosis of a small intestinal NET with lymph node and liver metastases. The inclusion criteria of metastatic or inoperable disease aligns with the patient’s current situation. While the study doesn't directly compare Everolimus vs PRRT, understanding prognostic and predictive factors in NET patients could inform the choice between these therapies. The study has 15 publications and posted results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors; Carcinoma;Endocrine",
        "intervention": "",
        "url": "https://clinicaltrials.gov/study/NCT05168631",
        "publications": {
          "nct_id": "NCT05168631",
          "study_title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
          "publications_found": 15,
          "publications": [
            {
              "pmid": "18565894",
              "citation": "Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/18565894/"
            },
            {
              "pmid": "25312765",
              "citation": "Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015 Feb 15;121(4):589-97. doi: 10.1002/cncr.29099. Epub 2014 Oct 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25312765/"
            },
            {
              "pmid": "28448665",
              "citation": "Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28448665/"
            },
            {
              "pmid": "27759713",
              "citation": "Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27759713/"
            },
            {
              "pmid": "25723112",
              "citation": "Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25723112/"
            },
            {
              "pmid": "28955403",
              "citation": "de M Rego JF, de Medeiros RSS, Braghiroli MI, Galvao B, Neto JEB, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, de Castro G Jr, Hoff PM, Filho DR, Costa FP, Riechelmann RP. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience. 2017 Sep 11;11:767. doi: 10.3332/ecancer.2017.767. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28955403/"
            },
            {
              "pmid": "26482044",
              "citation": "Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016 Feb 15;22(4):1011-7. doi: 10.1158/1078-0432.CCR-15-0548. Epub 2015 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26482044/"
            },
            {
              "pmid": "28018101",
              "citation": "Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28018101/"
            },
            {
              "pmid": "28456055",
              "citation": "Girardi DM, Silva ACB, Rego JFM, Coudry RA, Riechelmann RP. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev. 2017 May;56:28-35. doi: 10.1016/j.ctrv.2017.04.002. Epub 2017 Apr 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28456055/"
            },
            {
              "pmid": "27259015",
              "citation": "Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016 Sep;40(9):1192-202. doi: 10.1097/PAS.0000000000000662.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27259015/"
            },
            {
              "pmid": "29629316",
              "citation": "Oberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg. 2018 Feb;7(1):20-27. doi: 10.21037/gs.2017.10.08.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29629316/"
            },
            {
              "pmid": "27594907",
              "citation": "Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016 Aug 8;10:662. doi: 10.3332/ecancer.2016.662. eCollection 2016.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27594907/"
            },
            {
              "pmid": "28194228",
              "citation": "Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenco Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience. 2017 Jan 26;11:716. doi: 10.3332/ecancer.2017.716. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28194228/"
            },
            {
              "pmid": "19097774",
              "citation": "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19097774/"
            },
            {
              "pmid": "7165009",
              "citation": "Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7165009/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT06638931",
        "title": "Agnostic Therapy in Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes 'pure or mixed neuroendocrine tumors with neuroendocrine component' within its list of eligible cancers, directly matching the patient's diagnosis of a neuroendocrine tumor. While the patient's ECOG and age are not specified, the inclusion criteria require ECOG 0 or 1 and age over 18, which are plausible for this patient. The patient has progressed on prior treatment (surgery) and is now considering further therapy (Everolimus or PRRT), fitting the requirement of progression after standard treatment. The study has published results in peer-reviewed journals, indicating good scientific quality.",
        "condition": "Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor",
        "intervention": "Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT06638931",
        "publications": {
          "nct_id": "NCT06638931",
          "study_title": "Agnostic Therapy in Rare Solid Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "25542058",
              "citation": "Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporte I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25542058/"
            },
            {
              "pmid": "35320644",
              "citation": "Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35320644/"
            },
            {
              "pmid": "30204247",
              "citation": "DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30204247/"
            },
            {
              "pmid": "26028255",
              "citation": "Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26028255/"
            },
            {
              "pmid": "34534430",
              "citation": "Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34534430/"
            },
            {
              "pmid": "32919526",
              "citation": "Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32919526/"
            },
            {
              "pmid": "30955977",
              "citation": "Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30955977/"
            },
            {
              "pmid": "32101663",
              "citation": "Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32101663/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02236910",
        "title": "An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a somatostatin receptor positive NET of the small intestine with liver metastases, which aligns with the study's inclusion criteria for patients with somatostatin receptor positive tumors. The patient's history of surgery doesn't automatically exclude them, and the study allows for prior radionuclide therapy (which could include DOTATOC PET scan). The intervention, Lu-DOTA-TATE, is a potential alternative to Everolimus or further PRRT, addressing the clinical question. Finally, the study has published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Carcinoma",
        "intervention": "Lu-DOTA-TATE",
        "url": "https://clinicaltrials.gov/study/NCT02236910",
        "publications": {
          "nct_id": "NCT02236910",
          "study_title": "An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "34110489",
              "citation": "Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol. 2022 Jan;148(1):225-236. doi: 10.1007/s00432-021-03672-w. Epub 2021 Jun 10.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34110489/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02923934",
        "title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes intestinal neuroendocrine tumors, which matches the patient's diagnosis of a duodenal NET with liver metastases. The inclusion criteria of ECOG performance status 1 and prior systemic therapy being permitted (with a washout period) do not appear to rule the patient out, although the patient's ECOG and prior therapies are not specified. The combination of ipilimumab and nivolumab represents a potentially useful treatment option to consider alongside Everolimus or PRRT, especially given the limited treatment options for NETs. The study is completed and has published results, indicating good scientific quality.",
        "condition": "Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm",
        "intervention": "Ipilimumab; Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT02923934",
        "publications": {
          "nct_id": "NCT02923934",
          "study_title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "32729929",
              "citation": "Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32729929/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03074513",
        "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes a 'Neuroendocrine tumors, extrapancreatic basket' which aligns with the patient's diagnosis of a small intestinal NET. The patient's G2 tumor grade is within the inclusion criteria (Grade 1 or 2). While the patient's ECOG and age are unknown, the study requires ECOG 0 or 1, and the patient's prior therapies are unspecified, the study allows for any number of prior therapies. Atezolizumab and bevacizumab represent a potentially useful treatment option to consider alongside Everolimus or PRRT. The study has published results, indicating good scientific quality.",
        "condition": "Appendix Adenocarcinoma; Human Papillomavirus-Related Anal Squamous Cell Carcinoma; Human Papillomavirus-Related Cervical Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis; Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma; Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor; Recurrent Merkel Cell Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Stage III Merkel Cell Carcinoma AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Carcinoma AJCC v7; Stage IV Pleural Malignant Mesothelioma AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVC Nasopharyngeal Carcinoma AJCC v7; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "intervention": "Atezolizumab; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study",
        "url": "https://clinicaltrials.gov/study/NCT03074513",
        "publications": {
          "nct_id": "NCT03074513",
          "study_title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35389428",
              "citation": "Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jun 1;8(6):904-909. doi: 10.1001/jamaoncol.2022.0212.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35389428/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02754297",
        "title": "Personalized PRRT of Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with progressive/symptomatic NET, which aligns with the patient's diagnosis of a metastatic small bowel NET. The inclusion criteria regarding prior treatment (intolerance or refusal of other palliative treatments) do not appear to exclude the patient, who is currently considering Everolimus or PRRT. The patient's DOTATOC PET scan suggests somatostatin receptor expression, a requirement for PRRT. Given the clinical question of whether to pursue PRRT, this study evaluating personalized PRRT is directly applicable, and the presence of a publication indicates good scientific quality.",
        "condition": "Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine",
        "intervention": "177Lu-Octreotate",
        "url": "https://clinicaltrials.gov/study/NCT02754297",
        "publications": {
          "nct_id": "NCT02754297",
          "study_title": "Personalized PRRT of Neuroendocrine Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30506283",
              "citation": "Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742. doi: 10.1007/s00259-018-4209-7. Epub 2018 Nov 30.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30506283/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03728361",
        "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors (NET) in cohort 2, which aligns with the patient's diagnosis of a small intestinal NET with lymph node and liver metastases. The inclusion criteria appear to not rule out the patient based on the available information – the patient likely has measurable disease, and the study allows for both treatment-naive and pre-treated patients. The combination of nivolumab and temozolomide represents a potentially useful alternative to everolimus or PRRT, offering a different treatment approach. Finally, the study has published results, indicating good scientific quality.",
        "condition": "Grade I Neuroendocrine Carcinoma; Grade II Neuroendocrine Carcinoma; Grade III Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Neuroendocrine Carcinoma; Recurrent Small Cell Lung Carcinoma; Refractory Small Cell Lung Carcinoma; Lung Cancer Stage IV; Large Cell Neuroendocrine Carcinoma; Neuroendocrine Tumors; Small Cell Lung Cancer Metastatic; Small-cell Lung Cancer",
        "intervention": "Nivolumab; Temozolomide",
        "url": "https://clinicaltrials.gov/study/NCT03728361",
        "publications": {
          "nct_id": "NCT03728361",
          "study_title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33234490",
              "citation": "Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, Ghattas C, Shah M, Konda B, Verschraegen CF, Wesolowski R, Behbehani GK, Carson WE, Otterson GA. Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. Clin Lung Cancer. 2021 Jul;22(4):e487-e497. doi: 10.1016/j.cllc.2020.10.018. Epub 2020 Nov 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33234490/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03217097",
        "title": "MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents",
        "status": "COMPLETED",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with duodeno-pancreatic NETs, which aligns with the patient's diagnosis of a small intestinal NET. The inclusion criteria do not explicitly exclude the patient based on the limited information available (prior surgery is allowed, and no age or ECOG information is exclusionary). The intervention, oxaliplatin-based chemotherapy, is a potential alternative to everolimus or PRRT being considered for the patient. The study is completed, has published results, and the publication suggests a potential predictive biomarker (MGMT) to guide treatment choice, making it a scientifically sound and potentially useful resource.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Oxaliplatin-based chemotherapy; Alkylating-based chemotherapy",
        "url": "https://clinicaltrials.gov/study/NCT03217097",
        "publications": {
          "nct_id": "NCT03217097",
          "study_title": "MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30824408",
              "citation": "Lemelin A, Barritault M, Hervieu V, Payen L, Peron J, Couvelard A, Cros J, Scoazec JY, Bin S, Villeneuve L, Lombard-Bohas C, Walter T; MGMT-NET investigators. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET). Dig Liver Dis. 2019 Apr;51(4):595-599. doi: 10.1016/j.dld.2019.02.001. Epub 2019 Feb 14.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30824408/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT04969887",
        "title": "Combination Immunotherapy in Rare Cancers Under InvesTigation",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes Grade 3 NETs, and the patient has a G2 NET with metastases, potentially progressing to a higher grade. While the patient's grade is G2, the study does include G3 NETs and may consider the patient based on disease progression. The inclusion criteria of ECOG ≤1 and prior systemic therapy ≤1 are likely met (though ECOG is unspecified). Immunotherapy with ipilimumab and nivolumab is a potentially useful treatment option to consider alongside Everolimus or PRRT, especially given the limited response to somatostatin analogs indicated by the DOTATOC PET scan. The study has published results, indicating good scientific quality.",
        "condition": "Advanced Biliary Tract Cancer; Neuroendocrine Tumors; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor",
        "intervention": "Ipilimumab; Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT04969887",
        "publications": null
      },
      {
        "nct_id": "NCT05255133",
        "title": "A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment",
        "status": "COMPLETED",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes GEP-NET patients, which aligns with the patient's diagnosis of a small intestinal NET. The patient's clinical question focuses on whether to use Everolimus, and this study investigates Everolimus treatment in combination with SSA. While the patient's ECOG and age are unknown, the inclusion criteria of ECOG ≤ 2 is reasonable, and the study has published results, indicating good scientific quality. The exclusion criteria regarding prior Everolimus treatment is a potential concern, but the patient's prior therapies are unspecified, so we cannot rule them out based on this criterion alone.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Liquid biopsies; Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)",
        "url": "https://clinicaltrials.gov/study/NCT05255133",
        "publications": {
          "nct_id": "NCT05255133",
          "study_title": "A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "34759042",
              "citation": "Boons G, Vandamme T, Marien L, Lybaert W, Roeyen G, Rondou T, Papadimitriou K, Janssens K, Op de Beeck B, Simoens M, Demey W, Dero I, Van Camp G, Peeters M, Op de Beeck K. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up. Clin Cancer Res. 2022 Jan 15;28(2):338-349. doi: 10.1158/1078-0432.CCR-21-2291. Epub 2021 Nov 10.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34759042/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03454763",
        "title": "Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study focuses on PRRT for Sstr2-positive neuroendocrine tumors, which aligns with the patient's diagnosis of a G2 NET. The inclusion criteria allow for patients with progressive disease refractory to standard treatments, and the patient is currently considering Everolimus or PRRT. The ECOG performance status requirement of <=2 and other lab value criteria are likely met, though the patient's ECOG and baseline labs are not specified. The study has published results, indicating good scientific quality. Therefore, this study could provide valuable information to guide the patient's treatment decision.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "PRRT every 5 weeks; PRRT every 8-10 weeks",
        "url": "https://clinicaltrials.gov/study/NCT03454763",
        "publications": {
          "nct_id": "NCT03454763",
          "study_title": "Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "34980502",
              "citation": "Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M Jr, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schuller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR Jr, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer. 2022 Feb;162:221-236. doi: 10.1016/j.ejca.2021.09.046. Epub 2021 Dec 31.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34980502/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ]
  },
  {
    "patient_id": "4",
    "patient_data": {
      "ID": 4,
      "beschreibung": "P-NET G2-Case, Compete Trial analog",
      "tumorboard_datum ": 8.2016,
      "main_diagnosis_text": "NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)\nCT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n08/2015 Start Somatuline\n06/2016 DOTATOC PET: Progress der Lebermetastasen, starke Speicherung der Leberläsionen.",
      "Fragestellung": "Weitere Therapie, Everolimus oder PRRT?",
      "Empfehlung": "PRRT starten."
    },
    "matches_found": 15,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03278379",
        "title": "Avelumab in G2-3 NET",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes Grade 2 NETs of pancreatic origin, matching the patient's diagnosis. The inclusion criteria allow for patients who have received prior somatostatin analogue therapy (which the patient has) and up to two prior lines of systemic therapy, and the ECOG performance status requirement of 0-2 is likely met. Avelumab represents a different treatment approach than Everolimus or PRRT, offering a potential alternative for this patient, and the study has published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Avelumab",
        "url": "https://clinicaltrials.gov/study/NCT03278379",
        "publications": {
          "nct_id": "NCT03278379",
          "study_title": "Avelumab in G2-3 NET",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35504244",
              "citation": "Chan DL, Rodriguez-Freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A, Nguyen K, Singh S. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. Eur J Cancer. 2022 Jul;169:74-81. doi: 10.1016/j.ejca.2022.03.029. Epub 2022 May 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35504244/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02973204",
        "title": "Circulating Tumor Cells and Tumor DNA in HCC and NET",
        "status": "COMPLETED",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. It explicitly includes patients with NET, and the patient has a NET diagnosis. The patient's case of pancreatic NET with liver metastases aligns with one of the study's patient cohorts (pancreatic NET before Everolimus treatment), and the clinical question directly addresses whether Everolimus is a suitable next step. The study has 16 publications, indicating good scientific quality and published results. While the patient's prior Somatuline treatment isn't specifically addressed in the inclusion/exclusion criteria, it doesn't explicitly exclude them, and the study focuses on patients *before* starting treatment with Everolimus, which is a relevant consideration for this patient.",
        "condition": "Carcinoma, Hepatocellular; Neuroendocrine Tumors",
        "intervention": "Sorafenib; Radiofrequency ablation (RFA) or surgery; Everolimus; Lanreotide",
        "url": "https://clinicaltrials.gov/study/NCT02973204",
        "publications": {
          "nct_id": "NCT02973204",
          "study_title": "Circulating Tumor Cells and Tumor DNA in HCC and NET",
          "publications_found": 16,
          "publications": [
            {
              "pmid": "25140861",
              "citation": "Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jantti C, Sundin A, Sundlov A, Thiis-Evensen E, Knigge U. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25140861/"
            },
            {
              "pmid": "21374666",
              "citation": "Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21374666/"
            },
            {
              "pmid": "22846862",
              "citation": "Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol. 2012 Aug;39(4):449-60. doi: 10.1053/j.seminoncol.2012.05.012.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22846862/"
            },
            {
              "pmid": "21224371",
              "citation": "Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M, Meyer T. Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res. 2011 Jan 15;17(2):337-45. doi: 10.1158/1078-0432.CCR-10-1776. Epub 2011 Jan 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21224371/"
            },
            {
              "pmid": "23248251",
              "citation": "Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013 Jan 20;31(3):365-72. doi: 10.1200/JCO.2012.44.2905. Epub 2012 Dec 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23248251/"
            },
            {
              "pmid": "23616258",
              "citation": "Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013 Nov;133(9):2165-71. doi: 10.1002/ijc.28230. Epub 2013 Jun 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23616258/"
            },
            {
              "pmid": "25009297",
              "citation": "Guo W, Yang XR, Sun YF, Shen MN, Ma XL, Wu J, Zhang CY, Zhou Y, Xu Y, Hu B, Zhang X, Zhou J, Fan J. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res. 2014 Sep 15;20(18):4794-805. doi: 10.1158/1078-0432.CCR-14-0251. Epub 2014 Jul 9.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25009297/"
            },
            {
              "pmid": "24185511",
              "citation": "Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec;45(12):1483-6. doi: 10.1038/ng.2821. Epub 2013 Nov 3.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24185511/"
            },
            {
              "pmid": "21252315",
              "citation": "Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011 Mar 4;331(6021):1199-203. doi: 10.1126/science.1200609. Epub 2011 Jan 20.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21252315/"
            },
            {
              "pmid": "24148618",
              "citation": "Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24148618/"
            },
            {
              "pmid": "25900181",
              "citation": "Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris TJ, Salomoni P, Luong TV, Davidson B, Beck S, Thirlwell C. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015 Jun;22(3):L13-8. doi: 10.1530/ERC-15-0108. Epub 2015 Apr 21. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25900181/"
            },
            {
              "pmid": "19496710",
              "citation": "Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009 Jun;9(6):739-45. doi: 10.1586/era.09.41.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19496710/"
            },
            {
              "pmid": "25822088",
              "citation": "Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25822088/"
            },
            {
              "pmid": "24705333",
              "citation": "Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW Jr, Alizadeh AA, Diehn M. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. Epub 2014 Apr 6.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24705333/"
            },
            {
              "pmid": "25103305",
              "citation": "Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014 Dec 15;120(24):3896-901. doi: 10.1002/cncr.28964. Epub 2014 Aug 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25103305/"
            },
            {
              "pmid": "25991462",
              "citation": "Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open. 2015 May 19;5(5):e008248. doi: 10.1136/bmjopen-2015-008248.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25991462/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT05459844",
        "title": "A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a G2 pancreatic NET with liver metastases, which falls within the study's inclusion criteria for G1/G2 GEP-NETs. While the patient's prior therapies and ECOG status are not fully specified, the study requires prior Octreotide LAR treatment with progression, which the patient received, and an ECOG of 0 or 1, which is plausible. The study compares Lutetium[177Lu] Oxodotreotide to Octreotide LAR, directly addressing the clinical question of whether to pursue PRRT (Lutetium[177Lu] Oxodotreotide) versus continuing Octreotide. The study is a Phase 3 trial with published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Lutetium[177Lu] Oxodotreotide Injection; Octreotide LAR",
        "url": "https://clinicaltrials.gov/study/NCT05459844",
        "publications": null
      },
      {
        "nct_id": "NCT03012620",
        "title": "Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes 'rare malignant neuroendocrine tumour' patients, specifically those refractory to prior lines of treatment, which aligns with the patient's history of progressing disease on Somatuline. The inclusion criteria regarding metastatic disease and prior therapy (refractory after 2 lines for poorly differentiated, 4 lines for well differentiated, 2 lines for carcinoid) do not appear to rule out this patient, although the exact number of prior lines is unspecified. Pembrolizumab represents a potentially useful treatment option to consider alongside Everolimus or PRRT. The study is a Phase 2 trial with published results, indicating good scientific quality.",
        "condition": "Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal; NK/T-cell Lymphoma",
        "intervention": "Pembrolizumab",
        "url": "https://clinicaltrials.gov/study/NCT03012620",
        "publications": null
      },
      {
        "nct_id": "NCT02724540",
        "title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, matching the patient's diagnosis. The inclusion criteria regarding liver metastases (≥ 1.0 cm) and tumor burden seem potentially met given the patient's history of liver metastases, although precise measurements are missing. The patient is currently on somatostatin analogues, fitting the inclusion criteria regarding symptom control or progressive disease. The interventions (embolization techniques) offer alternative local therapies to consider alongside Everolimus or PRRT, addressing the clinical question. Finally, the study is completed, has published results, and a peer-reviewed publication, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumor, Malignant; Liver Metastases",
        "intervention": "Bland Embolization; Transarterial chemoembolization; Drug Eluting Beads Embolization",
        "url": "https://clinicaltrials.gov/study/NCT02724540",
        "publications": {
          "nct_id": "NCT02724540",
          "study_title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30016989",
              "citation": "Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018 Jul 17;19(1):390. doi: 10.1186/s13063-018-2782-5.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30016989/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03079440",
        "title": "TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with pancreatic neuroendocrine tumors, matching the patient's diagnosis. While the patient's ECOG and age are unknown, the study allows for ECOG 0-2. The patient's tumor is G2, but the study focuses on G3 tumors with Ki-67 <60%, and the patient's Ki-67 is not specified, meaning they may be eligible. The intervention, TEMCAP, is a chemotherapy regimen that could be considered as an alternative to Everolimus or PRRT, addressing the clinical question. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors; Neuroendocrine Carcinoma; Temozolomide; Capecitabine",
        "intervention": "TEMCAP",
        "url": "https://clinicaltrials.gov/study/NCT03079440",
        "publications": {
          "nct_id": "NCT03079440",
          "study_title": "TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors",
          "publications_found": 5,
          "publications": [
            {
              "pmid": "26731334",
              "citation": "Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186-94. doi: 10.1159/000443172. Epub 2016 Jan 5. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26731334/"
            },
            {
              "pmid": "24771552",
              "citation": "Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014 Sep 15;120(18):2814-23. doi: 10.1002/cncr.28721. Epub 2014 Apr 25.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24771552/"
            },
            {
              "pmid": "22967994",
              "citation": "Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22967994/"
            },
            {
              "pmid": "20824724",
              "citation": "Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011 Jan 15;117(2):268-75. doi: 10.1002/cncr.25425. Epub 2010 Sep 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/20824724/"
            },
            {
              "pmid": "21456005",
              "citation": "Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011 Oct 15;117(20):4617-22. doi: 10.1002/cncr.26124. Epub 2011 Mar 31.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21456005/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT05168631",
        "title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, matching the patient's diagnosis of a pancreatic NET with liver metastases. The inclusion criteria of metastatic or inoperable disease aligns with the patient's condition. While the study is retrospective and doesn't offer a direct treatment, identifying prognostic and predictive factors could inform the decision between Everolimus or PRRT, addressing the clinical question. The presence of 15 publications indicates good scientific quality and reported results.",
        "condition": "Neuroendocrine Tumors; Carcinoma;Endocrine",
        "intervention": "",
        "url": "https://clinicaltrials.gov/study/NCT05168631",
        "publications": {
          "nct_id": "NCT05168631",
          "study_title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
          "publications_found": 15,
          "publications": [
            {
              "pmid": "18565894",
              "citation": "Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/18565894/"
            },
            {
              "pmid": "25312765",
              "citation": "Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015 Feb 15;121(4):589-97. doi: 10.1002/cncr.29099. Epub 2014 Oct 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25312765/"
            },
            {
              "pmid": "28448665",
              "citation": "Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28448665/"
            },
            {
              "pmid": "27759713",
              "citation": "Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27759713/"
            },
            {
              "pmid": "25723112",
              "citation": "Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25723112/"
            },
            {
              "pmid": "28955403",
              "citation": "de M Rego JF, de Medeiros RSS, Braghiroli MI, Galvao B, Neto JEB, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, de Castro G Jr, Hoff PM, Filho DR, Costa FP, Riechelmann RP. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience. 2017 Sep 11;11:767. doi: 10.3332/ecancer.2017.767. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28955403/"
            },
            {
              "pmid": "26482044",
              "citation": "Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016 Feb 15;22(4):1011-7. doi: 10.1158/1078-0432.CCR-15-0548. Epub 2015 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26482044/"
            },
            {
              "pmid": "28018101",
              "citation": "Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28018101/"
            },
            {
              "pmid": "28456055",
              "citation": "Girardi DM, Silva ACB, Rego JFM, Coudry RA, Riechelmann RP. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev. 2017 May;56:28-35. doi: 10.1016/j.ctrv.2017.04.002. Epub 2017 Apr 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28456055/"
            },
            {
              "pmid": "27259015",
              "citation": "Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016 Sep;40(9):1192-202. doi: 10.1097/PAS.0000000000000662.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27259015/"
            },
            {
              "pmid": "29629316",
              "citation": "Oberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg. 2018 Feb;7(1):20-27. doi: 10.21037/gs.2017.10.08.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29629316/"
            },
            {
              "pmid": "27594907",
              "citation": "Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016 Aug 8;10:662. doi: 10.3332/ecancer.2016.662. eCollection 2016.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27594907/"
            },
            {
              "pmid": "28194228",
              "citation": "Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenco Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience. 2017 Jan 26;11:716. doi: 10.3332/ecancer.2017.716. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28194228/"
            },
            {
              "pmid": "19097774",
              "citation": "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19097774/"
            },
            {
              "pmid": "7165009",
              "citation": "Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7165009/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT06638931",
        "title": "Agnostic Therapy in Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The inclusion criteria specifically list \"Pure or mixed neuroendocrine tumors with neuroendocrine component\", directly encompassing the patient's diagnosis of a pancreatic NET. While the patient's ECOG and age are not specified, the study requires an ECOG of 0 or 1 and age over 18, which are plausible for this patient. The patient has progressed on somatuline and is considering Everolimus or PRRT, meaning they have progressed on prior treatment and could meet the inclusion criterion of progression after standard treatment. The study has published results in peer-reviewed journals, indicating good scientific quality, and nivolumab represents a potentially useful alternative treatment option given the patient's progression.",
        "condition": "Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor",
        "intervention": "Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT06638931",
        "publications": {
          "nct_id": "NCT06638931",
          "study_title": "Agnostic Therapy in Rare Solid Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "25542058",
              "citation": "Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporte I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25542058/"
            },
            {
              "pmid": "35320644",
              "citation": "Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35320644/"
            },
            {
              "pmid": "30204247",
              "citation": "DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30204247/"
            },
            {
              "pmid": "26028255",
              "citation": "Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26028255/"
            },
            {
              "pmid": "34534430",
              "citation": "Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34534430/"
            },
            {
              "pmid": "32919526",
              "citation": "Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32919526/"
            },
            {
              "pmid": "30955977",
              "citation": "Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30955977/"
            },
            {
              "pmid": "32101663",
              "citation": "Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32101663/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02236910",
        "title": "An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a somatostatin receptor positive NET of the pancreas with liver metastases, which aligns with the study's inclusion criteria for patients with somatostatin receptor positive tumors. The patient's prior treatment with somatuline doesn't explicitly exclude them, and the study is evaluating Lu-DOTA-TATE as a potential therapy, which is a reasonable consideration given the patient's progression on somatuline and the question of whether to pursue Everolimus or PRRT. The study has published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Carcinoma",
        "intervention": "Lu-DOTA-TATE",
        "url": "https://clinicaltrials.gov/study/NCT02236910",
        "publications": {
          "nct_id": "NCT02236910",
          "study_title": "An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "34110489",
              "citation": "Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol. 2022 Jan;148(1):225-236. doi: 10.1007/s00432-021-03672-w. Epub 2021 Jun 10.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34110489/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02923934",
        "title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, including pancreatic NETs, which matches the patient's diagnosis. While the patient's ECOG and age are not specified, the inclusion criteria of ECOG 1 and age >=18 do not immediately rule them out. The patient has progressed on somatuline and is considering Everolimus or PRRT, making immunotherapy with Ipilimumab and Nivolumab a potentially useful alternative treatment option. The study is completed and has published results, indicating good scientific quality.",
        "condition": "Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm",
        "intervention": "Ipilimumab; Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT02923934",
        "publications": {
          "nct_id": "NCT02923934",
          "study_title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "32729929",
              "citation": "Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32729929/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03074513",
        "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes a 'Neuroendocrine tumors, pancreatic basket' and a 'Neuroendocrine tumors, extrapancreatic basket', matching the patient's diagnosis of a pancreatic NET. The patient's G2 NET falls within the grade 1 or 2 inclusion criteria. While the patient's ECOG and age are unknown, the study's inclusion criteria regarding performance status (ECOG 0 or 1) and lab values do not immediately rule the patient out, assuming they meet those requirements. Atezolizumab and bevacizumab represent a different treatment approach (immunotherapy/anti-angiogenesis) than somatuline or PRRT, offering a potentially useful alternative. The study has published results, indicating good scientific quality.",
        "condition": "Appendix Adenocarcinoma; Human Papillomavirus-Related Anal Squamous Cell Carcinoma; Human Papillomavirus-Related Cervical Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis; Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma; Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor; Recurrent Merkel Cell Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Stage III Merkel Cell Carcinoma AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Carcinoma AJCC v7; Stage IV Pleural Malignant Mesothelioma AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVC Nasopharyngeal Carcinoma AJCC v7; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "intervention": "Atezolizumab; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study",
        "url": "https://clinicaltrials.gov/study/NCT03074513",
        "publications": {
          "nct_id": "NCT03074513",
          "study_title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35389428",
              "citation": "Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jun 1;8(6):904-909. doi: 10.1001/jamaoncol.2022.0212.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35389428/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02113800",
        "title": "Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The patient has a G2 NET with liver metastases, and the study includes NET G2 patients who have progressed. The intervention, Everolimus, is being considered as a potential next step in the patient's treatment. While the patient's ECOG and age are unknown, the study's criteria are not immediately exclusionary based on the provided information. The study is a completed Phase II trial with published results, indicating good scientific quality.",
        "condition": "Poorly Differentiated Malignant Neuroendocrine Carcinoma; Neuroendocrine Carcinoma, Grade 3; Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3; Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3; Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)",
        "intervention": "Everolimus (Afinitor®)",
        "url": "https://clinicaltrials.gov/study/NCT02113800",
        "publications": {
          "nct_id": "NCT02113800",
          "study_title": "Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33973550",
              "citation": "Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33973550/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02754297",
        "title": "Personalized PRRT of Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with progressive NET, which aligns with the patient's diagnosis of a pancreatic NET with liver metastases and documented progression on Somatuline. The inclusion criteria regarding prior therapies are met as the patient's prior treatment isn't restrictive. The patient's tumor expresses somatostatin receptors (based on the DOTATOC PET scan), fulfilling a key inclusion criterion. PRRT with 177Lu-Octreotate is a reasonable therapeutic option being considered for this patient, and the study's personalized approach could be beneficial. Finally, the study has published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine",
        "intervention": "177Lu-Octreotate",
        "url": "https://clinicaltrials.gov/study/NCT02754297",
        "publications": {
          "nct_id": "NCT02754297",
          "study_title": "Personalized PRRT of Neuroendocrine Tumors",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30506283",
              "citation": "Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742. doi: 10.1007/s00259-018-4209-7. Epub 2018 Nov 30.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30506283/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03728361",
        "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors (NET) in Cohort 2, matching the patient's diagnosis. The inclusion criteria appear to not rule out the patient based on the limited information available (ECOG 0-1, adequate organ function are likely met, stable somatostatin analogue use is allowed). The combination of nivolumab and temozolomide represents a potentially useful alternative treatment option to Everolimus or PRRT, given the patient's progression on somatuline. The study has published results, indicating good scientific quality.",
        "condition": "Grade I Neuroendocrine Carcinoma; Grade II Neuroendocrine Carcinoma; Grade III Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Neuroendocrine Carcinoma; Recurrent Small Cell Lung Carcinoma; Refractory Small Cell Lung Carcinoma; Lung Cancer Stage IV; Large Cell Neuroendocrine Carcinoma; Neuroendocrine Tumors; Small Cell Lung Cancer Metastatic; Small-cell Lung Cancer",
        "intervention": "Nivolumab; Temozolomide",
        "url": "https://clinicaltrials.gov/study/NCT03728361",
        "publications": {
          "nct_id": "NCT03728361",
          "study_title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "33234490",
              "citation": "Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, Ghattas C, Shah M, Konda B, Verschraegen CF, Wesolowski R, Behbehani GK, Carson WE, Otterson GA. Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. Clin Lung Cancer. 2021 Jul;22(4):e487-e497. doi: 10.1016/j.cllc.2020.10.018. Epub 2020 Nov 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33234490/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03217097",
        "title": "MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents",
        "status": "COMPLETED",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes duodeno-pancreatic NETs, which matches the patient's diagnosis of a pancreatic NET. The inclusion criteria allow for prior treatment with somatostatin analogs (the patient received Somatuline), and the study doesn't explicitly exclude patients based on age or ECOG performance status (though these are not specified in the patient data). The intervention, oxaliplatin-based chemotherapy, is a potential alternative to everolimus or PRRT being considered for the patient. Finally, the study is completed, has published results, and the publication suggests a potential predictive biomarker (MGMT) to guide treatment choice, making it a scientifically sound study.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Oxaliplatin-based chemotherapy; Alkylating-based chemotherapy",
        "url": "https://clinicaltrials.gov/study/NCT03217097",
        "publications": {
          "nct_id": "NCT03217097",
          "study_title": "MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30824408",
              "citation": "Lemelin A, Barritault M, Hervieu V, Payen L, Peron J, Couvelard A, Cros J, Scoazec JY, Bin S, Villeneuve L, Lombard-Bohas C, Walter T; MGMT-NET investigators. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET). Dig Liver Dis. 2019 Apr;51(4):595-599. doi: 10.1016/j.dld.2019.02.001. Epub 2019 Feb 14.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30824408/"
            }
          ],
          "status": "from_study_data"
        }
      }
    ]
  },
  {
    "patient_id": "5",
    "patient_data": {
      "ID": 5,
      "beschreibung": "P-NET G2-Case Initial",
      "tumorboard_datum ": 6.2015,
      "main_diagnosis_text": "NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)\nCT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n06/2015 DOTATOC PET: starke Speicherung der Läsionen.",
      "Fragestellung": "Weitere Therapie, Somatuline oder PRRT?",
      "Empfehlung": "PRRT starten."
    },
    "matches_found": 15,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03278379",
        "title": "Avelumab in G2-3 NET",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with advanced, Grade 2-3 NETs of gastroenteropancreatic origin, which matches the patient's pancreatic NET (G2) with metastasis. The inclusion criteria allow for patients who have received up to 2 prior lines of systemic therapy, and do not explicitly exclude somatostatin analogs (though they are not counted as a line of therapy). The patient's clinical question regarding Somatuline versus PRRT suggests they are considering systemic therapy, and Avelumab could be a potential alternative. The study is a completed Phase 2 trial with published results, indicating a reasonable level of scientific quality.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Avelumab",
        "url": "https://clinicaltrials.gov/study/NCT03278379",
        "publications": {
          "nct_id": "NCT03278379",
          "study_title": "Avelumab in G2-3 NET",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "35504244",
              "citation": "Chan DL, Rodriguez-Freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A, Nguyen K, Singh S. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. Eur J Cancer. 2022 Jul;169:74-81. doi: 10.1016/j.ejca.2022.03.029. Epub 2022 May 2.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35504244/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02730104",
        "title": "Community-based Neuroendocrine Tumor (NET) Research Study",
        "status": "COMPLETED",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes pancreatic NET patients with locally advanced or metastatic disease, matching the patient's diagnosis of a pancreatic G2 NET with lymph node and liver metastases. The inclusion criteria do not explicitly exclude the patient based on the provided information; the patient's tumor grade (G2) fits, and prior somatostatin analogue use is permitted. The intervention, lanreotide depot, directly addresses the clinical question of whether to continue somatuline treatment. Finally, the study is completed, has published results, and a publication is listed, indicating good scientific quality.",
        "condition": "Gastroenteropancreatic Neuroendocrine Tumors",
        "intervention": "",
        "url": "https://clinicaltrials.gov/study/NCT02730104",
        "publications": {
          "nct_id": "NCT02730104",
          "study_title": "Community-based Neuroendocrine Tumor (NET) Research Study",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "36136274",
              "citation": "Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. Oncol Ther. 2022 Dec;10(2):463-479. doi: 10.1007/s40487-022-00208-1. Epub 2022 Sep 22.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/36136274/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT04727723",
        "title": "Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a G2 NET of the pancreas with liver metastases, which falls under the GEP-NET category included in the study. The patient's DOTATOC PET scan showing strong uptake indicates somatostatin receptor positivity, a key inclusion criterion. While the patient's age, ECOG status, and prior therapies are unknown, the study only excludes patients naïve to Lutathera®, which doesn't immediately disqualify this patient. Given the clinical question regarding Somatuline versus PRRT, and Lutathera being a PRRT option, the intervention is potentially useful. The study has published results, indicating good scientific quality.",
        "condition": "Gastroenteropancreatic Neuroendocrine Tumor",
        "intervention": "Lutathera®",
        "url": "https://clinicaltrials.gov/study/NCT04727723",
        "publications": null
      },
      {
        "nct_id": "NCT03012620",
        "title": "Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes 'rare malignant neuroendocrine tumour' patients, specifically those refractory to prior lines of treatment, which aligns with the patient's pancreatic NET with liver and lymph node metastases and the clinical question regarding further therapy after initial diagnosis. While the patient's prior therapies and ECOG status are unknown, the inclusion criteria do not immediately exclude them based on the provided information. Pembrolizumab, an anti-PD-1 antibody, represents a potentially useful treatment option for a patient who has progressed or is refractory to standard therapies. The study is a Phase 2 trial with published results, indicating good scientific quality.",
        "condition": "Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal; NK/T-cell Lymphoma",
        "intervention": "Pembrolizumab",
        "url": "https://clinicaltrials.gov/study/NCT03012620",
        "publications": null
      },
      {
        "nct_id": "NCT03012789",
        "title": "Surgical Intervention and the NETest",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes G2 NETs of gastro-enteropancreatic origin, matching the patient’s pancreatic NET. The inclusion criteria allow for both treatment-naïve and previously treated patients, and a WHO performance status of ≤2 is likely met given the limited information available. While the intervention is surgery, the study's focus on correlating surgical resection quality with circulating NET levels and recurrence could inform treatment decisions regarding further interventions like PRRT or Somatuline, especially if surgery is considered. The study has 3 publications and posted results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumor; Gastroenteropancreatic",
        "intervention": "Surgery",
        "url": "https://clinicaltrials.gov/study/NCT03012789",
        "publications": {
          "nct_id": "NCT03012789",
          "study_title": "Surgical Intervention and the NETest",
          "publications_found": 3,
          "publications": [
            {
              "pmid": "26456125",
              "citation": "Modlin IM, Frilling A, Salem RR, Alaimo D, Drymousis P, Wasan HS, Callahan S, Faiz O, Weng L, Teixeira N, Bodei L, Drozdov I, Kidd M. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 2016 Jan;159(1):336-47. doi: 10.1016/j.surg.2015.06.056. Epub 2015 Oct 9.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26456125/"
            },
            {
              "pmid": "26032155",
              "citation": "Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol. 2015 Aug;110(8):1223-32. doi: 10.1038/ajg.2015.160. Epub 2015 Jun 2.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26032155/"
            },
            {
              "pmid": "26370353",
              "citation": "Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015 Sep;16(9):e435-e446. doi: 10.1016/S1470-2045(15)00186-2.",
              "type": "RESULT",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26370353/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02724540",
        "title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, and the patient has a pancreatic NET with liver metastases, fitting the tumor type criteria. The inclusion criteria regarding liver metastasis size and tumor burden seem potentially met, and the patient's clinical question directly addresses a treatment option (Somatuline vs. PRRT) where embolization could be considered, especially given uncontrolled symptoms or progressive disease. The study is Phase 2, completed, has published results, and the publication indicates good scientific quality. While the patient's ECOG and age are unknown, the study allows for ECOG 0-2, and the patient is likely over 18.",
        "condition": "Neuroendocrine Tumor, Malignant; Liver Metastases",
        "intervention": "Bland Embolization; Transarterial chemoembolization; Drug Eluting Beads Embolization",
        "url": "https://clinicaltrials.gov/study/NCT02724540",
        "publications": {
          "nct_id": "NCT02724540",
          "study_title": "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "30016989",
              "citation": "Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018 Jul 17;19(1):390. doi: 10.1186/s13063-018-2782-5.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30016989/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03079440",
        "title": "TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with pancreatic neuroendocrine tumors, matching the patient's diagnosis. While the patient's ECOG and age are unknown, the study accepts ECOG 0-2. The patient's tumor is G2, but the study focuses on G3 tumors with Ki-67 <60%, and the patient's Ki-67 is unknown, so they are not ruled out. The intervention, TEMCAP, is a chemotherapy regimen that could be considered as an alternative to somatuline or PRRT, addressing the clinical question. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors; Neuroendocrine Carcinoma; Temozolomide; Capecitabine",
        "intervention": "TEMCAP",
        "url": "https://clinicaltrials.gov/study/NCT03079440",
        "publications": {
          "nct_id": "NCT03079440",
          "study_title": "TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors",
          "publications_found": 5,
          "publications": [
            {
              "pmid": "26731334",
              "citation": "Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186-94. doi: 10.1159/000443172. Epub 2016 Jan 5. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26731334/"
            },
            {
              "pmid": "24771552",
              "citation": "Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014 Sep 15;120(18):2814-23. doi: 10.1002/cncr.28721. Epub 2014 Apr 25.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/24771552/"
            },
            {
              "pmid": "22967994",
              "citation": "Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22967994/"
            },
            {
              "pmid": "20824724",
              "citation": "Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011 Jan 15;117(2):268-75. doi: 10.1002/cncr.25425. Epub 2010 Sep 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/20824724/"
            },
            {
              "pmid": "21456005",
              "citation": "Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011 Oct 15;117(20):4617-22. doi: 10.1002/cncr.26124. Epub 2011 Mar 31.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21456005/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT05168631",
        "title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors, matching the patient's diagnosis of a pancreatic NET with lymph node and liver metastases. The inclusion criteria of metastatic or inoperable disease aligns with the patient's presentation. While the study is retrospective and doesn't offer a direct treatment, identifying prognostic and predictive factors could inform the decision between Somatuline and PRRT, addressing the clinical question. The presence of 15 publications indicates good scientific quality and reported results.",
        "condition": "Neuroendocrine Tumors; Carcinoma;Endocrine",
        "intervention": "",
        "url": "https://clinicaltrials.gov/study/NCT05168631",
        "publications": {
          "nct_id": "NCT05168631",
          "study_title": "Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors",
          "publications_found": 15,
          "publications": [
            {
              "pmid": "18565894",
              "citation": "Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/18565894/"
            },
            {
              "pmid": "25312765",
              "citation": "Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015 Feb 15;121(4):589-97. doi: 10.1002/cncr.29099. Epub 2014 Oct 13.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25312765/"
            },
            {
              "pmid": "28448665",
              "citation": "Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28448665/"
            },
            {
              "pmid": "27759713",
              "citation": "Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27759713/"
            },
            {
              "pmid": "25723112",
              "citation": "Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25723112/"
            },
            {
              "pmid": "28955403",
              "citation": "de M Rego JF, de Medeiros RSS, Braghiroli MI, Galvao B, Neto JEB, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, de Castro G Jr, Hoff PM, Filho DR, Costa FP, Riechelmann RP. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience. 2017 Sep 11;11:767. doi: 10.3332/ecancer.2017.767. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28955403/"
            },
            {
              "pmid": "26482044",
              "citation": "Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016 Feb 15;22(4):1011-7. doi: 10.1158/1078-0432.CCR-15-0548. Epub 2015 Oct 19.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26482044/"
            },
            {
              "pmid": "28018101",
              "citation": "Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28018101/"
            },
            {
              "pmid": "28456055",
              "citation": "Girardi DM, Silva ACB, Rego JFM, Coudry RA, Riechelmann RP. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev. 2017 May;56:28-35. doi: 10.1016/j.ctrv.2017.04.002. Epub 2017 Apr 17.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28456055/"
            },
            {
              "pmid": "27259015",
              "citation": "Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016 Sep;40(9):1192-202. doi: 10.1097/PAS.0000000000000662.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27259015/"
            },
            {
              "pmid": "29629316",
              "citation": "Oberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg. 2018 Feb;7(1):20-27. doi: 10.21037/gs.2017.10.08.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29629316/"
            },
            {
              "pmid": "27594907",
              "citation": "Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016 Aug 8;10:662. doi: 10.3332/ecancer.2016.662. eCollection 2016.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27594907/"
            },
            {
              "pmid": "28194228",
              "citation": "Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenco Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience. 2017 Jan 26;11:716. doi: 10.3332/ecancer.2017.716. eCollection 2017.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28194228/"
            },
            {
              "pmid": "19097774",
              "citation": "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19097774/"
            },
            {
              "pmid": "7165009",
              "citation": "Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7165009/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT06638931",
        "title": "Agnostic Therapy in Rare Solid Tumors",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The inclusion criteria explicitly list \"Pure or mixed neuroendocrine tumors with neuroendocrine component\" making it a tumor fit. While the patient's ECOG and age are unknown, the study requires ECOG 0 or 1, and age >=18, which are plausible for this patient. The patient has progressed on prior therapies (implied by the question of further therapy) and the study requires progression after prior treatment, making the intervention potentially useful. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.",
        "condition": "Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor",
        "intervention": "Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT06638931",
        "publications": {
          "nct_id": "NCT06638931",
          "study_title": "Agnostic Therapy in Rare Solid Tumors",
          "publications_found": 8,
          "publications": [
            {
              "pmid": "25542058",
              "citation": "Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporte I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25542058/"
            },
            {
              "pmid": "35320644",
              "citation": "Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35320644/"
            },
            {
              "pmid": "30204247",
              "citation": "DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30204247/"
            },
            {
              "pmid": "26028255",
              "citation": "Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26028255/"
            },
            {
              "pmid": "34534430",
              "citation": "Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34534430/"
            },
            {
              "pmid": "32919526",
              "citation": "Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32919526/"
            },
            {
              "pmid": "30955977",
              "citation": "Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30955977/"
            },
            {
              "pmid": "32101663",
              "citation": "Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32101663/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02236910",
        "title": "An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a somatostatin receptor positive NET of the pancreas with liver metastases, which directly fits the study's inclusion criteria for patients with somatostatin receptor positive tumors. The patient's DOTATOC PET scan confirms strong somatostatin receptor expression. While the patient's age and ECOG status are unknown, the study allows for patients aged 14-90 with an ECOG of ≤2. The intervention, Lu-DOTA-TATE, is a potential alternative or addition to somatuline or PRRT, addressing the clinical question. Finally, the study has published results, indicating good scientific quality.",
        "condition": "Neuroendocrine Carcinoma",
        "intervention": "Lu-DOTA-TATE",
        "url": "https://clinicaltrials.gov/study/NCT02236910",
        "publications": {
          "nct_id": "NCT02236910",
          "study_title": "An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "34110489",
              "citation": "Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol. 2022 Jan;148(1):225-236. doi: 10.1007/s00432-021-03672-w. Epub 2021 Jun 10.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34110489/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT02923934",
        "title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study is clinically relevant for the patient. The study explicitly includes pancreatic neuroendocrine tumors, matching the patient's diagnosis. While the patient's age, ECOG status, and prior therapies are not fully specified, the inclusion criteria allow for prior systemic therapy and do not have strict age limitations (>=18 years). The ECOG requirement of 1 is unknown but potentially achievable. The intervention (Ipilimumab and Nivolumab) represents a potential treatment option beyond somatuline or PRRT, offering a different mechanism of action. The study is completed and has published results, indicating good scientific quality.",
        "condition": "Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm",
        "intervention": "Ipilimumab; Nivolumab",
        "url": "https://clinicaltrials.gov/study/NCT02923934",
        "publications": {
          "nct_id": "NCT02923934",
          "study_title": "A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",
          "publications_found": 1,
          "publications": [
            {
              "pmid": "32729929",
              "citation": "Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814.",
              "type": "DERIVED",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32729929/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT04696042",
        "title": "Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs",
        "status": "COMPLETED",
        "phase": "N/A",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a G2 pancreatic NET with metastases, which falls under the GEP-NET inclusion criteria. The patient's tumor grade matches the study's G1/G2 requirement. While prior therapies aren't specified, the exclusion of prior somatostatin analogues *could* be a limiting factor, but the study allows for prior Lanreotide treatment up to 5 months. The intervention, Lanreotide autogel, directly addresses the clinical question of whether to continue Somatuline (Lanreotide) therapy. The study is completed and has 5 publications, indicating good scientific quality and available results.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "Lanreotide autogel",
        "url": "https://clinicaltrials.gov/study/NCT04696042",
        "publications": {
          "nct_id": "NCT04696042",
          "study_title": "Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs",
          "publications_found": 5,
          "publications": [
            {
              "pmid": "23091441",
              "citation": "Gastrointestinal Pathology Study Group of Korean Society of Pathologists; Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park DY, Lee JH, Chang H, Jung ES, Kim HK, Jin SY, Choi JH, Gu MJ, Kim S, Kang MS, Cho CH, Park MI, Kang YK, Kim YW, Yoon SO, Bae HI, Joo M, Moon WS, Kang DY, Chang SJ. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat. 2012 Sep;44(3):157-65. doi: 10.4143/crt.2012.44.3.157. Epub 2012 Sep 30.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/23091441/"
            },
            {
              "pmid": "21659833",
              "citation": "Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). Am J Clin Oncol. 2012 Dec;35(6):549-56. doi: 10.1097/COC.0b013e31821dee0f.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21659833/"
            },
            {
              "pmid": "26731013",
              "citation": "Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Oberg K; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172-85. doi: 10.1159/000443167. Epub 2016 Jan 5. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26731013/"
            },
            {
              "pmid": "30536151",
              "citation": "Kang J, Yoo C, Hwang HS, Hong SM, Kim KP, Kim SY, Hong YS, Kim TW, Ryoo BY. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. Invest New Drugs. 2019 Aug;37(4):763-770. doi: 10.1007/s10637-018-0710-x. Epub 2018 Dec 10.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/30536151/"
            },
            {
              "pmid": "25014687",
              "citation": "Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25014687/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT03870399",
        "title": "Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a G2 pancreatic NET, which is included in the study's definition of well-differentiated NETs. While the patient's ECOG and age are unknown, the study accepts ECOG 0-2. The patient's prior therapies are unspecified, but the study allows prior treatment except for current tamoxifen use. The clinical question regarding Somatuline vs. PRRT suggests the patient may have exhausted standard options, aligning with the study's inclusion of patients with no further established treatments. Tamoxifen represents a novel approach, and the study has 21 publications with posted results, indicating good scientific quality.",
        "condition": "Neuroendocrine Tumors; Progesterone Receptor Positive Tumor; Estrogen Receptor Positive Tumor",
        "intervention": "Tamoxifen",
        "url": "https://clinicaltrials.gov/study/NCT03870399",
        "publications": {
          "nct_id": "NCT03870399",
          "study_title": "Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression",
          "publications_found": 21,
          "publications": [
            {
              "pmid": "18565894",
              "citation": "Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/18565894/"
            },
            {
              "pmid": "9737302",
              "citation": "Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998 Sep 5;352(9130):799-805. doi: 10.1016/S0140-6736(98)02286-7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/9737302/"
            },
            {
              "pmid": "19845567",
              "citation": "Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88. doi: 10.1111/j.1365-2036.2009.04174.x. Epub 2009 Oct 21.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19845567/"
            },
            {
              "pmid": "25317881",
              "citation": "Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Oct 16;371(16):1556-7. doi: 10.1056/NEJMc1409757. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25317881/"
            },
            {
              "pmid": "19704057",
              "citation": "Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/19704057/"
            },
            {
              "pmid": "1356613",
              "citation": "Viale G, Doglioni C, Gambacorta M, Zamboni G, Coggi G, Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992 Nov 1;70(9):2268-77. doi: 10.1002/1097-0142(19921101)70:93.0.co;2-x.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/1356613/"
            },
            {
              "pmid": "26976979",
              "citation": "Zimmermann N, Lazar-Karsten P, Keck T, Billmann F, Schmid S, Brabant G, Thorns C. Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases. Anticancer Res. 2016 Mar;36(3):921-4.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26976979/"
            },
            {
              "pmid": "25076292",
              "citation": "Estrella JS, Broaddus RR, Mathews A, Milton DR, Yao JC, Wang H, Rashid A. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug;138(8):1027-36. doi: 10.5858/arpa.2013-0195-OA.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25076292/"
            },
            {
              "pmid": "28597868",
              "citation": "Kim SJ, An S, Lee JH, Kim JY, Song KB, Hwang DW, Kim SC, Yu E, Hong SM. Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients. J Pathol Transl Med. 2017 Jul;51(4):388-395. doi: 10.4132/jptm.2017.03.19. Epub 2017 Jun 8.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28597868/"
            },
            {
              "pmid": "2800857",
              "citation": "Arganini M, Spinelli C, Cecchini GM, Miccoli P. Long term treatment with tamoxifen for metastatic carcinoid tumor. Acta Chir Belg. 1989 Jul-Aug;89(4):209-11.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/2800857/"
            },
            {
              "pmid": "7059114",
              "citation": "Myers CF, Ershler WB, Tannenbaum MA, Barth R. Tamoxifen and carcinoid tumor. Ann Intern Med. 1982 Mar;96(3):383. doi: 10.7326/0003-4819-96-3-383_1. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7059114/"
            },
            {
              "pmid": "25702678",
              "citation": "Biasco E, Antonuzzo A, Galli L, Baldi GG, Derosa L, Marconcini R, Farnesi A, Ricci S, Falcone A. Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen. Tumori. 2015 Mar 20;101(1):e24-8. doi: 10.5301/tj.5000259.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25702678/"
            },
            {
              "pmid": "7231519",
              "citation": "Stathopoulos GP, Karvountzis GG, Yiotis J. Tamoxifen in carcinoid syndrome. N Engl J Med. 1981 Jul 2;305(1):52. doi: 10.1056/NEJM198107023050115. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/7231519/"
            },
            {
              "pmid": "6200021",
              "citation": "Moertel CG, Engstrom PF, Schutt AJ. Tamoxifen therapy for metastatic carcinoid tumor: a negative study. Ann Intern Med. 1984 Apr;100(4):531-2. doi: 10.7326/0003-4819-100-4-531. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/6200021/"
            },
            {
              "pmid": "10334533",
              "citation": "Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 May;17(5):1474-81. doi: 10.1200/JCO.1999.17.5.1474.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/10334533/"
            },
            {
              "pmid": "16148022",
              "citation": "Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005 Oct;16(10):1569-83. doi: 10.1093/annonc/mdi326. Epub 2005 Sep 7.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/16148022/"
            },
            {
              "pmid": "22173704",
              "citation": "Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012 Feb;7(2):306-15. doi: 10.1097/JTO.0b013e31823c5c16.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/22173704/"
            },
            {
              "pmid": "28018101",
              "citation": "Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28018101/"
            },
            {
              "pmid": "6438654",
              "citation": "Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25(2):127-205. doi: 10.1016/0163-7258(84)90043-3. No abstract available.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/6438654/"
            },
            {
              "pmid": "9875847",
              "citation": "Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23;95(7):927-37. doi: 10.1016/s0092-8674(00)81717-1.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/9875847/"
            },
            {
              "pmid": "21306238",
              "citation": "Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.",
              "type": "BACKGROUND",
              "url": "https://pubmed.ncbi.nlm.nih.gov/21306238/"
            }
          ],
          "status": "from_study_data"
        }
      },
      {
        "nct_id": "NCT05050942",
        "title": "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The patient has a well-differentiated pancreatic NET with liver metastases, which falls under the GEP-NET inclusion criteria. While the patient's ECOG and age are unknown, the study allows ECOG 0-2. The patient's prior therapies are unspecified, but the exclusion criteria regarding prior SSA treatment and PRRT need to be carefully considered based on the patient's history. The study compares different somatostatin analogs, directly addressing the clinical question of whether to continue Somatuline or consider PRRT, and the presence of recent publications indicates good scientific quality.",
        "condition": "Gastro-enteropancreatic Neuroendocrine Tumor",
        "intervention": "CAM2029; Octreotide LAR; Lanreotide ATG",
        "url": "https://clinicaltrials.gov/study/NCT05050942",
        "publications": null
      },
      {
        "nct_id": "NCT03873870",
        "title": "68Ga-DOTATATE PET for Management of Neuroendocrine Tumors",
        "status": "COMPLETED",
        "phase": "NA",
        "dataset_source": "HasResults-false",
        "relevance_score": 1.0,
        "relevance_reason": "This study appears clinically relevant for the patient. The study explicitly includes patients with NETs, and the patient has a confirmed diagnosis of pancreatic NET with metastases. The patient's clinical question revolves around further therapy options (Somatuline or PRRT), and the study investigates the use of 68Ga-DOTATATE PET scans for restaging patients where PRRT is being considered (Group C), directly addressing the clinical question. The patient's ability to undergo a PET/CT scan without sedation is unknown, but assuming they can, they likely meet the inclusion criteria. The study is completed, has published results, and therefore meets the quality criteria.",
        "condition": "Neuroendocrine Tumors",
        "intervention": "68Ga -DOTATATE PET scans",
        "url": "https://clinicaltrials.gov/study/NCT03873870",
        "publications": null
      }
    ]
  }
]